eli lilly company corporate citizenship report 200506 full website content table content overview 38 access medicine increasing access medicine united state 3 welcome report increasing access medicine internationally report public sector need 4 chairman message 42 investing community improving patient outcome 6 business helping patient mental illness company profile helping child diabetes indirect economic benefit supporting scientific education research product providing disaster relief value chain issue encouraging employee commitment key indicator 46 workforce workplace 12 corporate citizenship approach responsibility toward employee corporate citizenship lilly upholding human right engaging stakeholder 49 supply chain key issue supplier diversity auditing supplier thirdparty contractor 16 research development research priority 51 public policy clinical trial corporate political contribution data disclosure lilly pac animal research lobbying advocacy lilly membership business 21 protecting health safety environment trade association health safety environmental management product life cycle company information hse performance review 56 fiveyear data set 32 ethical marketing use governance product promotion 58 award recognition product liability issue product promotion issue 59 history lilly principle directtoconsumer communication 62 feedback 2 overview welcome report welcome eli lilly company corporate citizen workforce workplace including employ ship report addressing environmental social ment philosophy approach training economic aspect product operation development human right corporate citizenship reporting important supply chain including supplier diversity expression commitment transparency auditing supplier accountability tool dialogue stake holder hope find report valuable public policy including political lobbying con approach reporting evolving welcome tributions feedback via online survey wwwlillycom aboutcitizenship address listed inside third section summarizes award rec back cover report ognition lilly received fiveyear data set history information feedback pdf version full corporate citizen ship report also available web page report wwwlillycomaboutcitizenship separate summary development report influenced report focusing five key corporate citizenship global reporting initiative gri guideline issue available pdf report includes sustainability reporting wwwglobalreportingorg content summary report additional infor gri guideline designed meet need mation provide comprehensive picture diverse stakeholder throughout world business corporate citizenship performance provided useful guidance content report information locating gri ele tried make report relevant ment addressed website see gri content user focusing key issue associated index business role society page 10 data contained report 2005 cal report three main section first provides endar year include global operation unless chairman perspective corporate citizenship otherwise noted report include joint page 5 profile business product venture partially owned subsidiary leased facili issue page 6 discussion approach tie outsourced operation item unless corporate citizenship page 12 including stakeholder business arrangement would materially affect engagement page 14 governance system intent report code conduct page 13 accuracy validity information second section review approach perfor financial information prepared according mance relative following key issue generally accepted accounting principle gaap u subject internal research development including clinical trial accounting control system well external third disclosure animal research party audit ethical marketing use including promotion lilly us internal information technology ap pharmaceutical patient safety plication gather health safety environmen tal hse performance data site around access medicine world data extensively reviewed internal subjectmatter expert corporate hse investing community including global division time engage thirdparty example philanthropy community involve service review hse performance data ment protecting health safety environment cluding management system product life cycle approach performance 3 overview chairman message 40000 lilly employee energized practice corporate citizenship lilly three mission provide breakthrough medicine important part medical expertise enable people live longer healthier active life concern first strive execute fundamental rising cost health care access medi business highest standard includes cines drug safety promotional practice conducting medical research development eroded trust industry opened gap marketing product ethical transpar tween see company public ent manner manufacturing way view u protects patient environment health safety worker host community business exists serve patient trust essential 130 year lilly sought earn second seek employer choice public trust upholding highest standard use resource influence strengthen way make medicine conduct business local global community operate fulfill duty corporate citizen also recog nize trust earned party engage third look beyond operation un communicate know derstand global health need listening responding stakeholder help meet key enhancing capacity tackle daunting challenge delivering quality affordable believe making good progress health care 21st century area 2005 invested 3 billion research development meet goal inventing breakthrough medicine pioneered online clinical trial registry setting indus try benchmark transparency sharing research result recent independent audit confirmed posted 100 percent clinical trial information promised pro vide website wwwlillytrialscom 99 percent study posted schedule research development func tion receives guidance bioethics committee unique industry including two highly respected external bioethics expert lilly manufacturing reduced hazardous material purchase third 2003 2005 demonstrating progress towards environmen tal goal set 2010 2005 donated 1 million per day cash product u net wholesale price patient assistance program international humanitarian cause charitable endeav or included responding asian tsunami pakistan earthquake hurricane katrina disaster continued forge ahead sidney taurel chairman board chief executive officer 4 chairman message groundbreaking effort aimed stopping spread 130 year lilly multidrug resistant tuberculosis presentday global health threat sought earn public trust upholding challenge face industry highest standard way member global society go beyond company address half popula make medicine conduct tion developing country lack basic sanitation business fulfill duty without good health distant dream even corporate citizen u expertise training technol ogies healing firstrate 45 million american lack health care insurance step taking improve access medi cines respond need outlined report also pursuing business strategy aimed new vision delivering patient right drug right dose right time addi tion set goal reduce cost bring ing new medicine market third end decade determined help answer society need highquality affordable health care much remains done comprehensive answer challenge improving health care around world require coordinated action public private sector aid agency philan thropists lilly committed partner addressing challenge making difference million counting u sidney taurel chairman board chief executive officer 5 overview business company profile france germany ireland italy japan mexico puerto eli lilly company leading innovationdriven rico spain united kingdom united pharmaceutical corporation committed develop state skilled art making medicine ing growing portfolio bestinclass pharmaceuti employee make supply product sold 143 cal product help people live longer healthier country active life long history meaningful medical innovation notably lilly manufacturing consists complex operation treatment infection diabetes depression employee translate deep knowledge sci timeline page 59 illustrates significant event ence chemistry engineering production numer history development responsible ous discipline reliable manufacture public corporation additional information supply highquality safe effective medi corporate history significant medical break cines unique challenge associated throughs lilly visit lilly page making medicine place special emphasis wwwlillycom ensuring operation safe broadest sense wordfor patient employee envi lilly differenceour company ronment community operate mean health safety environmental lilly employee quality aspect making medicine start ing point united state 22611 intercontinental 12397 2005 lilly reached milestone effort improve quality manufacturing successful europe 6698 inspection u food drug administration japan 1536 lilly technology center lilly fully committed ensuring compliance current good manufactur ing practice required regulatory agency govern industry addition driving renewed cultural mindset compliance minimum expectation continuous improvement primary objective every site every day success effort led operational im provements important lasting impact company overall success lilly research development research division lilly research laboratory lrl responsible discovery develop 2005 42600 people worked lilly ment clinical evaluation commercialization worldwide lilly sale office 89 country potential new pharmaceutical product lrls 8400 market product approximately 143 people wide variety scientific discipline country also provide ongoing scientific support marketed product discovering developing innovative lilly publicly held company therapy many world unmet medical 50 year eli lilly company common stock need core lrls mission listed u new york pacific stock ex change london swiss stock exchange research development location united new york stock exchange share trade state include two site indiana indianapolis ticker symbol lly greenfield 2005 relocated lrl development operation west lafayette lilly manufacturing indianapolis also closed research operation 2005 global manufacturing operation located lillys research triangle park laboratory consisted 25 site 12500 manufactur north carolina relocated operation ing employee work site brazil china egypt indianapolis facility 6 business outside u research development lillys indirect economic contribution around facility located australia belgium canada world generally quantified make china england germany japan singapore less genuine farreaching however spain lilly conduct clinical research example 50 country joint venture employee make personal buying decision pay tax strengthen larger fabric elanco animal health community indiana alone indiana univer division lilly elanco animal health mar sity study determined lilly contributes kets product worldwide improve health 3 billion year state economy animal product marketed primarily cattle change lillys employment level poultry swine producer key operation sevenfold impact total employment state north america europe middle east africa personal philanthropy citizenship lilly asiapacific area latin america elanco employ employee also create significant impact en 2000 people market product courage lilly employeesand often provide 100 country company timeto serve volunteer notfor profit agency civic role corporate corporate financial information foundation many case match personal worldwide sale 2005 146 billion financial contribution employee group detailed information lillys financial per promote education health cultural enrich formance provided 2005 annual report mentadding million dollar year information lillys indirect economic benefit vital purpose found recognizing essential ingredient leadership community initiative lilly often lends time talent executive economicdevelop 2005 key financial indicator ment building project direct link worldwide sale 146453 business indianapolis u sale 77981 community lillys involvement often made difference attracting new corporate citizen europe middle east africa sale 41840 creating vital new public facility foreign country sale 26632 specific area health care lillys interest cost revenue 34742 impact work go well beyond sim ply selling pharmaceutical product used cash payment interest borrowing 320 appropriately innovative prescription drug often cash payment common stock dividend 16549 generate disproportionate saving form retained earnings increase 3026 health care eliminating need costly invasive surgery many case replacing long cash payment income tax 17800 stay hospital institution prevent ing appearance difficulttotreat condi full data set financial economic workplace safety tions later life therefore lilly invests consider community investment data 2005 available page 56 ably educate customer importance appropriate use medicine compliance indirect economic benefit medical treatment lilly lillys ability attract talented employee care lillyanswers program devote large tap scientific insight develop effective supplier scale resource expanding access pharmaceu relationship make sound investment deci tical patient regardless income sion depends large extent condition insurance status surrounding community fortunately lillys headquarters operation worldwide lilly privileged part many fine communi located exceptional communitiesplaces tiesand take part virtuous cycle economic combine aesthetic cultural appeal attractive social benefit city state region stable economic condition critical mass country related business benefit communi tiesand natural give back much return 7 business product human health lillys current product line address broad array world medical need table list pharmaceutical product currently market full prescribing information product use respective website link listed product webpage lilly trademark chemical identity generic name product use actos pioglitazone hydrochloride type 2 diabetes alimta pemetrexed injection malignant pleural mesothelioma 2ndline treatment nonsmallcell lung cancer byetta exenatide injection type 2 diabetes ceclor cefaclor infection cialis tadalafil male erectile dysfunction cymbalta duloxetine hydrochloride major depressive disorder diabetic peripheral neuropathic pain evista raloxifene hydrochloride prevention treatment osteoporosis postmenopausal woman forteo teriparatide recombinant dna origin osteoporosis gemzar gemcitabine hydrochloride nonsmallcell lung cancer pancreatic cancer bladder cancer approved u metastatic breast cancer recurrent ovarian cancer humalog insulin lispro injection recombinant dna origin treatment type 1 type 2 diabetes humatrope somatropin recombinant dna origin injection growth failure caused pediatric growth hormone deficiency replacement therapy adult growth hormone deficiency short stature caused turner syndrome idiopathic short stature humulin human insulin recombinant dna origin type 1 type 2 diabetes prozac fluoxetine hydrochloride depression obsessivecompulsive disorder bulimia panic disorder reopro abciximab centocor cardiovascular disease strattera atomoxetine hydrochloride attentiondeficit hyperactivity disorder adhd child adolescent adult symbyax olanzapine fluoxetine hydrochloride bipolar depression xigris drotrecogin alfa activated adult severe sepsis patient high risk death yentreve duloxetine hydrochloride stress urinary incontinence woman approved u zyprexa olanzapine schizophrenia shortterm treatment acute manic episode associated bipolar disorder schizophrenia longterm therapy maintenance combination therapy lithium valproate acute manic episode associated bipolar disorder bipolar maintenance actos registered trademark takeda chemical industry ltd used license takeda pharmaceutical america inc byetta trademark amylin pharmaceutical inc cialis trademark lilly icos llc product name appearing table u approved product except indicated u trademark different product name additional product marketed country 8 business animal health elanco animal health business unit market product worldwide improve health animal elancos current product line see list concentrate four area antibacterial parasiticides anticoc cidials productivity enhancer division develops market innovative technology use animal production care disease treatment prevention lilly trademark chemical identity generic name product use coban monensin sodium prevention coccidiosis common poultry disease elector spinosad cattle pouron dilutable spray controlling horn fly louse used dilutable spray house fly stable fly agricultural animal premise elector bait spinosad bait product control adult common house fly maxiban narasin nicarbiazin prevention coccidiosis common poultry disease micotil tilmicosin antibiotic used control respiratory disease cattle monteban narasin prevention coccidiosis common poultry disease optaflexx ractopamine hydrochloride feed ingredient used cattle increase live weight gain improve feed efficiency increase red meat yield paylean ractopamine hydrochloride feed ingredient used swine increase amount quality meat improving grain feed efficiency pulmotil tilmicosin phosphate antibiotic used control respiratory disease swine rumensin monensin sodium widely used efficient beef production tylan tylosin agricultural antibiotic used swine cattle poultry micotil product label including boxed warning see wwwelancocom call 18004284441 product name appearing table u approved product except indicated u trademark different product name additional product marketed country pharmaceutical pipeline search new drug risky uncertain guarantee information pipeline visit investor relation section lillycom 9 business value chain issue graphic summarizes major business activity related issue public concern 1 research discovery 2 development patient need assessment clinical trial hypothesis generation phase iii drug candidate development safety efficacy broader testing development manufacturing process regulatory approval goal better patient health 4 marketing distribution use 3 manufacturing promotion advertising production bulk active pharmaceutical ingredient customer engagement formulation filling finishing final product reporting feedback quality management safety efficacy health safety environmental management postmarketing clinical trial phase iv issue public concern research discovery development manufacturing marketing distribution use access medicine access medicine environmental aspect access medicine disease patient population energy water use product pricing availability targeted tested emission emerging market value drug created patient safety employee health safety patent protection drug already clinical trial pharmaceutical promotional practice market treat clinical trial disclosure environment including directtoconsumer equivalent condition animal testing supplier social marketing creating drug dubious environmental impact patientuse monitoring benefit drug counterfeiting reimportation 10 key indicator better 2004 worse 2004 2004 2005 trend financial worldwide sale u million 13858 14645 u sale 7669 7798 europe middle east africa sale 3858 4184 foreign country sale 2331 2663 stock price yearend 5675 5659 cash payment common stock dividend million 1540 1655 environment total energy consumed billion megajoules 1539 1601 normalized energy consumption megajoulesm sale 111 109 co2 equivalent emission thousand metric tonne 2215 2278 normalized co2 equivalent emission thousand kgm sale 160 156 total water consumed billion liter 370 354 normalized water consumption million litersm sale 267 242 hazardous material purchase kgm sale 807 593 total solid waste generated million kg 167 155 normalized solid waste generated thousand kgm sale 1202 1060 solvent emission loss percent use 046 040 total volatile organic compound emission thousand kg 976 913 serious environmental events1 11 3 workplace safety serious injury illness per 100 employee 16 17 serious ergonomic injury rate per 100 employees2 064 071 losttime case per 100 employee 057 065 lost workday per 100 employee 119 101 fleet safety lilly usa collision per million mile driven 779 721 community investment product donation million 338 453 cash contribution million 71 58 total contribution million 409 511 data global unless otherwise noted figure u dollar environmental data restated 2004 due improvement data reporting system use new waste category relevant pharmaceutical industry please see page 56 full data set 1 defined significant regulatory compliance event event result 2 definition serious injury equivalent u occupational complaint agency public event could create health administration recordable injury definition impairment aquatic life wildlife human life agency enforce ment action 11 overview corporate citizenship approach corporate citizenship lilly approach corporate citizenship influenced commitment corporate citizenship insepa aspiration company reputation rable basic business activity want lilly brand admired valued dodiscover develop manufacture market medi endeavor company stakehold cines help people live longer healthier erspatients employee physician shareholder active livesis described following section othersprefer work interact wwwlillycom go work know less say important set therefore action want high standard put system place help en stakeholder view lilly providing answer sure compliance law regulation society matter delivering breakthrough product expectation including medical expertise actively listening responding reliable trustworthy public policy compliance committee lilly board director review identifies appropriate brings attention board brand answer matter political social legal trend issue well compliance matter may impact commitment breakthrough product mean business operation financial performance public focus considerable investment research development new medicine image company committee also review responding market opportunity monitor make recommendation board also meeting unmet patient need corporate policy practice relate public policy compliance committee medical expertise enables research discov composed entirely independent director sup ery development new medicine also porting corporate staff includes vice president want share expertise discussed corporate affair office corporate secretary access medicine community investment vice president chief compliance officer section report maintain comprehensive program help en active listening responding describes sure compliance lilly policy voluntary com engage internal external stakehold mitments legal regulatory requirement er listening build understanding stake holder want need provides insight effort include establishing communicat market emerging policy regulatory ing standard procedure providing oversight issue community customer concern monitoring auditing performance incentive responding build trust assures stakehold taking disciplinary action necessary er concern taken seriously cornerstone program lillys code busi ness conduct red book page 32 employee pledge reliable trustworthy demon receive training red book must certify strates intention build trust company received read understand agree industry abide corporate citizenship principle page 12 draw know deliver commitment value policy standard summarize must engaged dedicated employee approach key issue public share lillys mission therefore lilly strives cre concern ate enriching workplace discussed workforce section page 46 reflects compa learn board director ny value philosophy provides employee senior management corporate governance opportunity make meaningful difference corporate governance portion website world work wwwinvestorlillycomgovernancecfm system sale marketing compliance discussed summary approach corporate citizenship detail marketing use section quire commitment accountability transparency report page 32 engagement employee customer stakeholder report key tool sup port approach hope spark dialogue 12 corporate citizenship approach shed light addressing chal touched byour company customer employee lenges opportunity pharmaceutical shareholder partner supplier community company 21st century integritywe conduct business way embrace highest standard honesty ethical behavior consistent mission strategic intent vision applicable law regulation honest dealing customer employee supplier mission competitor shareholder community provide customer answer matter excellencewe pursue pharmaceutical innovation innovative medicine information exceptional provide highquality product strive deliver customer service enable people live longer superior business result quest excellence healthier active life reflected unsurpassed focus quality strategic intent continuous search new way improve providing unmet need customer everything result customer around constant stream innovation world increasingly choose product grow competitor enabling u generate superior financial perfor mance benefit shareholder employee vision community live answer matter foundation promise customer deliver promise corporate responsibility principle listening understanding need cu tomers providing unmatched value provide business customer unmatched value create four dedicated providing customer answer dimension competitive advantage matter innovative medicine infor generating accelerating flow pharmaceuti mation exceptional customer service dedi cal product internal discovery external cation enable people live longer healthier source address customer unmet need active life discover develop product rigorous manufacturing supplying portfolio prod testing accordance highest scientific ucts everincreasing level quality service ethical standard strive create innovative product either firstinclass bestinclass providing information service delivery system fulfill clinical promise lilly label maximize value customer drive respect protect environment early sustained adoption product reliably manufacture supply high quality medicine safe effective create partnering obtain access highpotential mol ecules strengthen key capability thereby creat maintain safe healthful working condition ing value lilly partner price product mindful dual responsi could achieve bilities realize profit enable u invest discovery next generation organization adaptive highly flexible novative medicine permit patient allowing u respond internal external access value innovative medicine change bring family today governance business conduct corporate citizenship statement conduct forefront good corporate gover nance strong independent diverse core value membership board director longestablished core value guide eli lilly com comply law regulation every pany value country conduct business act af respect peoplewe maintain environment firmatively verify compliance built mutual respect openness individual conduct business activity respect integrity respect people includes concern people commitment diversity equal op interest people touchor portunity freedom exposure improper conduct discrimination 13 corporate citizenship approach select maintain relationship supplier engaging dialogue stakeholder based merit value product use variety technique communicate service work supplier stakeholder continue look way believe full compliance local law improve receive feedback report lillys standard social environmental eco important method directly communicating nomic performance soliciting feedback stakeholder safeguard make proper use nonpublic company thirdparty information successful way found engage access dialogue interested party include respect privacy individual personal infor mation lilly answer centerthis call center provides comply law regulation govern u customer accurate information lilly manner participate political product staff includes multilingual em process interact government official ployees offer language interpreter service public international organization support charitable need community community advisory panel indiana facility operate area talent manufacturing facility indianapolis clin resource make difference ton lafayette indiana established active community advisory panel made community transparency accountability stakeholder leader facility staff panel meet regularly listen respond forthrightly question throughout year discus item mutual inter criticism lilly pharmaceutical industry est serve forum community leader commit utmost updated new development lilly facility transparency timeliness aim lead recommend implement activity pro within industry improving response gram help meet mutual need question criticism face create maintain proper record adhere neighborhood meetingslilly employee organize highest standard external reporting practice visit neighbor several lilly plant site provid transparent clear accurate possible ing community member opportunity interact providing information stakeholder directly facility manager employee staff member many location help local engaging stakeholder emergency planning committee gather information nature lillys business together global conduct training enhance community safety reach mean vast array people institution government agency nongovernmental orga tour business gueststhe tour ambassador nizations interested choice make indiana site frontline employee make action take varied background interest lilly product support manufacturing adminis stakeholder mean often present u trative operation involved research fresh idea improvement listening provide historical tour lilly research facility responding stakeholder concern lilly im business guest interested learning prove transparency way business stakeholder employee surveysin 2005 lilly implemented business partner new annual survey method provides employee community member feedback result monthly basis rather employee surveying employee time governingauthorizing organization begun contacting employee patient business unit staggered basis throughout payer year provides senior management physician timely feedback employee attitude shareholder opinion 14 corporate citizenship approach voice alliancewe began survey 2000 due increased awareness impor tance research manufacturing alliance office alliance management performs 30 survey per year including 2000 respondent asking partner lilly employee involved partnership relation ship could improved alliance manager use result diagnostic survey determine well partnership performing 14 dif ferent measure data used design implement intervention targeted improving probability success partnership lilly surveyswe want know stakeholder thinking gather information many voice survey including voice customer government shareholder payer use information improve performance deliver promise reliable trustworthy company 15 key issue research development core mission meet health care need sponsor support medical research providing innovative medicine research purpose answering scientific question development process rd heart important relevant customer mission 2005 spent 3 billion medical component lilly accountable rd increase 12 percent 2004 repre design approval conduct scientific disclo senting 20 percent sale sure medical research sponsored lilly lilly make payment health care provider commitment high level rd investment legitimate reasonable necessary service provided wellrounded portfolio current amount fair market product healthy pipeline potential new value service performed product treat variety condition including lilly discloses publicly medical research result diabetes complication cancer heart disease significant patient health care provider osteoporosis obesity insomnia payerswhether favorable unfavorable product development pipeline see investor rela lilly productin accurate objective bal tion section wwwlillycom anced manner order customer make informed decision product pharmaceutical rd complex lengthy pro cess see page 17 order demonstrate safety addition bioethics committee see box efficacy drug law must tested composed 12 senior leader representing various laboratory living cell organism laborato lilly function two prominent external bioethics ry animal finally human social expert review ethical issue throughout rd ethical issue arise include process develops position specific ethical issue consults lilly research team disease target development medi position apply practice cines establish priority see research priority page 17 participates clinical trial patient safety protected see clinical trial page 17 lilly engages bioethics thought leader role animal play pharmaceutical research welfare protected see animal lilly standing bioethics committee research page 18 includes highly respected external bioethics ex perts well senior executive believe approach unique industry lillys bioeth lilly established policy standard protec ic committee formed 1999 focus tions throughout rd process ensure ethical matter pharmaceutical research patient need foremost time begin development committee comprised two principle medical research overarch external bioethicists tom l beauchamp phd ing statement lilly conduct georgetown university robert j levine md research relationship researcher yale university 12 senior internal leader share research development result fol representing lillys medical regulatory discovery lowing summary lillys principle medical legal corporate communication international research government affair global brand development platform function committee report jointly leadership corporate affair lilly lilly creates delivers innovative medicine research lab enable people live longer healthier ac tive life committee two major function devel lilly carefully conduct medical research gener ops lilly position bioethics issue ate important information regarding medi conduct international clinical trial cines promotes indication incorporated ongoing lilly training stan approved moreover lilly dard operating procedure committee also thoughtfully aligns medical research market responds timesensitive request advice ing activity provide answer matter particular issue drug development team customer 16 research development overview drug discovery development approval process take 10 15 year average experimental drug travel lab patient five 5000 compound enter preclinical testing make human testing one five compound tested people approved lillys investment bringing medicine market average 12 billion present trend continue cost could reach 2 billion adjusted inflation early part next decade clinical trial discoverypreclinical application regulatory agency testing phase phase ii phase iii regulator phase iv file marketing authorization file clinical trial application year 65 15 2 35 15 regulatory agency 20 100 100 500 test laboratory healthy patient 1000 5000 population animal study patient volunteer additional volunteer volunteer review post evaluate confirm process marketing assess safety determine effectiveness approval testing effectiveness monitor adverse purpose biological activity safety required look side reaction formulation dosage regulator effect longterm use success 5000 compound 5 enter 1 rate evaluated trial approved reference drug discovery development approval process pharma new medicine october 2004 page 43 research priority origin declaration helsinki make best use rd investment consistent good clinical practice largely concentrate therapeutic area applicable law regulation country deep expertise diabetes neuroscience car country study conducted diovascular oncology seek develop also follow standard published international pharmaceutical first class providing conference harmonisation technical treatment none existed andor best class quirements registration pharmaceutical improving existing treatment ap human use international ethical guideline proach new product may treat condi biomedical research involving human subject tions existing medicine pharmaceutical research manufacturer ever goal ensure medicine america principle conduct clinical trial meaningfully enhance treatment option available patient taken together principle standard set forth rule company follow protect clinical trial safety research participant integrity following discovery potential new treatment research enterprise applicable wherever clinical trial involving controlled testing human research conducted address issue used study whether experimental medi informed consent potential researcher conflict cine safe effective testing also determines interest disclosure result bioethics com effective dose new medicine side effect mittee also developed complementary position may experienced case whether clinical trial matter address specific issue experimental treatment safer effective conduct clinical trial international pharmaceutical option venue including developing country nature risk inherent pharmaceuti like pharmaceutical company con cal research human subject conduct ducting increasing amount medical research clinical trial adhere ethical principle developing country lilly sponsor conduct clinical trial investigator research 17 research development site meet appropriate standard medical care lilly clinical trial registry audited scientific rigor capable conducting trial accordance international stan mid2006 sec independent external auditor con dard good clinical practice lilly sponsor firmed lilly disclosed 100 percent study conduct clinical trial country said would 99 percent time little likelihood drug investi study posted schedule external audit also gated made available included broader look accuracy completeness data disclosed minor discrepancy noted additionally ethnic minority often suffer dispro portionately diabetes mental illness heart disease obesity cancer osteoarthritis tuberculosis animal research stroke disease yet patient tend lilly dedicated discovery development underrepresented clinical research highest quality product improve working include diverse mix patient health wellbeing people animal around medical research development improve un world committed careful derstanding importance diversity clinical thorough evaluation product using best research investigator selection trial place scientific technology available meeting com ment community awareness program mitment requires use animal recognize ethical scientific data disclosure obligation ensure responsible treatment believe disclosure information clini animal used research minimize number cal trial best interest patient animal involved pursue development medical community therefore lilly taken lead alternative test system continually evaluate ing role industry increased transpar new testing alternative time ency disclosure satisfactory mean totally eliminate use animal 2004 lilly first pharmaceutical company launch clinical trial registry wwwlillytrialscom animal use make publicly available detailed summary use animal grown rate clinical study phase phase iv research budget past 15 20 year sponsored connection marketed since early 1980s reduced overall medicine also first commit post animal usage nearly 50 percent time information initiation phase ii overall research effort increased significantly iii iv clinical trial append result annual rd expenditure growing ap completed industry standard call proximately 950 million 1993 3 billion posting trial dating 2002 later volun 2005 see figure however since 2000 tarily post trial dating 1994 later also number animal used increased slightly participate u government clinical trial reg availability genetically altered mouse rat istry wwwclinicaltrialsgov pharmaceutical fered new opportunity research innovation industry site wwwclinicalstudyresultsorg lilly animal use fraction r expenditure posted trial lilly includes summary result 400 trial design methodology result posted animalsmillions whether favorable unfavorable lil 300 ly product june 15 2006 144 studyresult summary 382 new initiated study 200 posted registry month site receives 100 10000 visit 0 1993 1995 1997 1999 2001 2003 2005 year animalsrd figure 18 research development case pharmaceutical company technique including cell binding system cell 97 percent animal use culture able eliminate many potential drug rodent see figure b purposely bred candidate getting stage animal test research strict policy prohibits use ing statistical method applied en animal unknown source including stray sure minimum number animal used rescue organization animal lilly complexity biological system cared close supervision veteri currently satisfactory mean eliminate narians trained animal caretaker use animal altogether lilly animal usage 2005 reduce since early 1980s lilly reduced animal usage significantly testing dog cat necessary use modern study design statistical rodent analysis ensures use animal po rabbit primate sible farm mammal bird refine take every measure minimize dis ectotherm comfort distress experimental design sample collection study conclusion parameter figure b carefully evaluated ensure model study refine ment study method reduce eliminate regulatory agency u food drug stress distress used refinement administration international conference harmonisation require u verify safety accreditation regulation inspection investigational treatment animal testing prior company maintains highest standard human administration fda regulation related animal care use globally united state lilly pharmacology toxicology information inves accredited association assess tigational new drug indicate certain data must ment accreditation laboratory animal care provided study using laboratory animal international 30 year term animal laboratory animal appear regulations3 also international conference lilly complies local state national law harmonisation ich m3 guideline entitled non regulation guideline use animal clinical safety study conduct human clinical research enforced relevant clinical trial pharmaceutical state section authority animal facility subject external 14 general principle study review inspection example u facility conducted least two mammalian specie subject unannounced site inspection vitro data may acceptable broad u department agriculture local authority series nonclinical pharmacology toxicology europe local national authority regularly inspect study necessary demonstrate efficacy animal facility association assess safety new medicine animal study continue ment accreditation laboratory animal care necessary new drug first given international also provides independent review human confirmation appropriate animal care use 3rs alternative u animal care use committee lilly committed responsible treatment includes independent thirdparty member ap laboratory animal application 3r prof oversees animal research activity care philosophy defined russell burch replace program similarly ethical committee uk ment reduction refinement germany review animal usage regularly inspect facility ensure people using animal ap replace replaced continue propriately qualified standard best practice place use animal vitro technique instituted facility mainte aspect research development nance improvement best practice depends improvement biomarkers vitro testtube internal external expertise 3 21 cfr ch 1 section 31223 8 ii section 31450 2 iv 19 research development training awareness communication animal user globally undergo thorough detailed training involving regulation 3rs use alter native experimental design animal husbandry behavior among others key veterinarian involved local national basis animal welfare organization technician recognized local regional national basis expertise improvement animal welfare lilly also support animal welfare award global basis identify recognize individu al substantially contributed research animal welfare company feel important communi cate use benefit use animal search veterinarian regularly go high school college discus research animal care use also regularly conduct animal care use seminar internally employee visitor con tractor addition key personnel country engaged involved animal care welfare organization 20 key issue protecting health safety environment health safety environmental management ance minimization environmental impact protecting environment protecting strategy allow individual lilly site around health safety work behalf world determine whether facility registration among highest priority lilly global appropriate facility corporate health safety environment hse policy see guide action supported three manufacturing facilitiesour location 36 global functional policy common hse morumbi brazil kinsale ireland mexico city sue process safety air pollution control soil mexicoand corporate em achieved certi groundwater protection page 22 emergen fication iso 14001 standard cy management page 22 addition participate several voluntary facility develops hse objective program related hse management including accordance local priority corporate osha voluntary performance program responsible commitment requirement goal site held care business roundtable new see accountable via hse management system change initiative page 23 includes oversight metric review site selfassessments facility also subject pe brief case study lillys speke uk facility illus riodic corporate hse internal audit team com trates facility continuously improving posed internal expert external auditor way manage environmental challenge information gathered auditing process page 23 basis annual report corporate compli ance committee corporate hse guidance goal improving hse performance council committee report progress issue corporate hse function working requiring senior management intervention function within company developed com policy strategy committee composed ceo prehensive corporate strategy drive performance senior staff public policy compli improvement strategy includes five hse goal ance committee board director 1 realize onethird reduction energy intensi plant expected health ty normalized sale corresponding green safety committee includes management house gas emission operation 2010 nonmanagement personnel employee compared baseline year 2003 progress encouraged report health safety practice date 13 percent reduction energy 11 percent believe could improved committee greenhouse gas emission work find solution reported practice 2 realize onethird reduction purchase implement solution hazardous material normalized sale 2010 innovative process facility follow apply u occupational safety design compared baseline year 2003 health administration osha recording progress date 38 percent reduction reporting occupational injury illness stan 3 achieve zero serious environmental event dard globally corporate data regarding accident 2007 progress date reduced 11 3 illness injury lost workday within 4 reduce serious ergonomic injury 50 percent company tracked continuously collected 2008 compared baseline year 2003 analyzed monthly progress date 11 percent reduction 5 attain onethird reduction collision per mil several facility certified iso 14001 lion mile 2010 implementation international organization standardization iso motor vehicle safety program top 10 sale based geneva switzerland established iso 14001 affiliate compared baseline year 2005 voluntary standard environmental manage ment system em goal iso 14001 corporate hse policy standard similar sustainability objective health care company committed demonstrate integrity hse management present future wellbeing people system continuous improvement compli environment live commitment pursued goal continuous improvement 21 protecting health safety environment guided following principle piping drum storage practice impact encourage expect employee environ past wastemanagement practice risk mentally responsible conduct work practice identified program implemented minimize safe manner accordance established risk program may include policy procedure practice con limited preparing spill prevention plan imple sidered essential measure performance menting secondary containment inspection employee contract employee working lilly repair program training employeescontractors premise external entity engaged pro spill response measure duction product also held account able expectation emergency response program practice build health safety environmental hse con lilly site required company policy regu siderations phase business including latory requirement emergency manage product technology discovery develop ment system includes risk assessment ment facility design operation maintenance identify critical risk addressed product delivery site emergency plan site required strive injuryfree workforce minimize assess readiness annually testing plan environmental impact implementation range tabletop exercise fullscale drill program facility surrounding com include community fire emergency agency munities reduce risk employee neighbor public large environment addition testing local site plan lilly comply applicable law regulation corporatelevel incident support team ready existing law regulation ad commit corporate resource event equate adopt standard consistent incident impact tangible asset people policy facility product site major exercise encourage promote waste minimization conducted past including working sustainable use natural resource recycling en manufacturing facility indiana u puerto ergy efficiency resource conservation resource rico france mexico recovery engage dialogue stakeholder drill test site emergency plan emergency commitment environment response team local agency past drill health safety lilly employee contractor also included local hospital law enforcement shareholder vendor customer visitor agency local emergency response agency community operate actively participate government agency corporate hse audit appropriate group ensure devel every three year corporate hse audit group opment implementation environmental completes assessment hse business risk health safety policy law regulation associated lilly global operation facility practice promote present future wellbeing assessment based primarily upon available people environment based site information including sound scientific judgment role site regularly assess report management previous audit biannual site selfassessment board director status compliance result principle external hse initiative corporate hse staff management input subscribe geographic location date previous audit protecting soil groundwater regulatory inspection history committed ensuring present processoperational change future operation negatively impact soil managementstaff change groundwater end established global soil groundwater protection policy result assessment used create requires facility conduct periodic risk plan following year well tentative assessment activity process could threeyear hse audit plan may revised result impact soil groundwater based major change one risk factor sessments must include evaluation possible spill activity leak equipment container 22 protecting health safety environment osha voluntary performance program lilly speke make environmental improvement u occupational safety health adminis trations osha voluntary performance program lillys speke facility merseyside uk set performancebased criterion managed safety put place several innovative system address health system invite site apply environmental challenge assesses applicant criterion osha verification includes application review wastewater facility engineer redesigned manufactur rigorous onsite evaluation team osha safety ing process cut zinc level facility wastewater health expert half without loss yield product quality result able comfortably meet ctd limit october 16 2002 lilly technology center zinc process recognized externally indianapolis indiana awarded star statusthe business commitment environment award highest level recognition osha program lilly technology center able demonstrate solvent recovery two bulk solvent butyl acetate excellent injury reduction health acetonitrile use speke site butyl acetate recycled distillation reused onsite following safety program place usbased lilly site continuous technical development recovery process considering participation initiative greater 98 percent efficient also invested heavily containment ensure minimize responsible care physical loss also made improvement 2005 lilly continued longstanding involve management acetonitrile segregating different ment american chemistry council respon waste stream containing solvent sible care initiative voluntary program aim disposed environmentally effective way achieving improvement health safety moved situation environmental hse performance participating waste solvent incinerated current situation manufacturing facility beyond level required solvent either recovered reuse u government highlight lillys effort site used secondary fuel subsequent energy recovery actively working proposal recover 2005 include performance external audit reuse solvent back process responsible care management system address hse security system lilly shared facil energy management speke us combined heat ity security plan local law enforcement agen power plant chp installed cies onsite visit also publish various efficient generation technology available hse performance metric via responsible care worked bp energy identify costeffective way metric website wwwresponsiblecareuscom reducing energy usage related emission begun replace old equipment energyefficient lillys manufacturing site kinsale ireland stateoftheart solution example recently speke uk also member responsible care placed chilled water generator system based respective country vapor absorption save 20 percent energy used previous system us available excess steam efficiently avoids use traditional refrigerant see change initiative associated atmospheric ozone impact lilly actively participating business round table new see change initiative social waste management speke facility produce around environment economy program designed 50 ton per day mycelium waste currently land encourage adoption sustainability principle filled uk implementation eu landfill directive business tool initiative asks american com revised regulation governing rule acceptance panies establish meet goal enhance waste landfill site third quarter 2007 mean society environment creating busi able continue landfilling material ness value together effort focused changing process site invested significant high priority challenge water quality energy resource find alternative environmentally sound efficiency another key goal initiative solution identified change process enable continued acceptance mycelium landfill eradication disease poverty something site interim measure identified co work toward every day quest develop new combustion mycelium longterm environmentally drug effort multipledrug friendly route detailed commercial discussion com resistant tuberculosis partnership page 39 mence shortly proposed service provider 23 protecting health safety environment product life cycle recovery change product mix supply committed making health safety chain action however number may fluctuate environmental hse consideration priority new yeartoyear due factor bulk raw material product development manufacturing identify inventory purchase cycle manage risk evaluating potential hse impact operation product well making pharmaceutical requires highly specialized hse capability supplier thirdparty op stateoftheart chemistry many case erations page 50 also mean looking opportu commercially viable alternative chemical nities make improvement throughout product process material use must develop life cycle development final disposal identify new alternative mean investing new science developing safer cleaner green chemistry process working cooperatively search al believe significant hse improve ternatives addition internal effort lilly ments result designing new product using position charter member green process minimize hse impact start chemistry institute pharmaceutical roundtable concept captured term green chemis multiply knowledge progress partnership try typically encompasses reducing material pharmaceutical company resource input special emphasis u ing fewer hazardous material green chemistry initiative also consider process safety industrial hygiene improve health safety profile product process integrating hse consideration development effort using green chemistry principle several way scientist engineer work apply uptodate science process selecting best process use producing medicine evaluate attribute predict future hse burden process along traditional crite ria yield quality cost equipment need set goal cut hazardous material pur environmental impact product service chase normalized sale onethird 2010 prevalence impact pharmaceutical compared 2003 drive progress toward goal environment matter increasing interest lil established specific material use efficiency ly public lilly one leading compa standard critical step product development ny pharmaceutical research manufacturer process efactor ratio material used per unit america phrma working provide guidance active pharmaceutical ingredient proposed disposal unused product manner manufacturing process evaluated key develop minimizes environmental impact low level ment milestone standard met certain drug product detected water checkpoint management review triggered scientist various location around world due standard believe unique indus improved testing technology reported concen try driving improvement efficiency new trations drug substance water extremely process example improved process identi low ranging part per trillion part per bil fied one pharmaceutical product cut material lion lilly proactive promoting science use estimated 13 million pound per year based examination issue support effort fullscale production address existing gap knowledge associated low concentration substance two year exceeded goal reducing water partnering phrma work hazardous material purchase defined compound ing scientific expert better understand listed u toxic release inventory 376 analyze impact trace level pharmaceutical percent result efficiency increase solvent environment 24 protecting health safety environment hse performance review health safety leading cause injury lilly affecting business sector globally ergonomic factor work place condition pose risk injury musculoskeletal system worker lilly con tinues aggressively implement comprehensive ergonomic injury reduction initiative called ergo swers program focus training employee raising employee awareness conducting proactive ergonomic assessment reducing eliminating factor cause greatest ergonomic risk within lilly facility unfortunately yet real ized reduction injury rate 2006 putting greater emphasis injury reduction office corporate center injury rate increased past year intend complete assessment 80 percent office worker location provide improved office equipment appropriate another area concern injury due motor vehicle accident 2005 number collision per million mile driven united state de creased 7 percent compared 2004 attribute decrease increased awareness among sale environmental event associate heightened commitment sale 2003 established metric serious envi management motor vehicle safety con ronmental event defined significant regulatory tinue use eightelement lilly motor vehicle compliance event event result com safety program pursue improvement goal plaint agency public event could create impairment aquatic life wildlife human life agency enforcement action goal zero environmental event 2007 reduced environmental event 13 2003 3 2005 data shown downward trend several reason including enhanced aware ness site controlling environmental event reducing variability operation environmental hazard review key operation capability assessment resulted improved process better rootcause analysis event occur 25 protecting health safety environment resource use volume total water intake operation declined 4 percent 2005 compared 2004 energy normalized sale decline 9 percent large multinational company energy use one half total water use occurs manu significant aspect environmental facturing operation indiana significant footprint total energy consumption 2005 proportion total manufacturing capacity approximately 16 billion megajoules 4 percent located continue monitor installation increase 2004 due addition capacity startup new equipment facility iden new facility normalized sale energy tify future water conservation opportunity use decreased 2 percent compared 2004 112 110 million megajoules per million dollar sale established 2010 goal realizing onethird reduction energy intensity energy consumption normalized sale cor responding reduction greenhouse gas emission operation compared baseline year 2003 biodiversity lilly continuously working protect habitat minimize impact operation ecosys tems committed engaging conservation project habitat enhancement 7300 acre land around globe well supporting conservation effort outside property water 2002 lilly began collecting data total tippecanoe laboratory indiana u amount water brought manufactur since 1997 lilly corporate member ing rd site worldwide either direct wildlife habitat council whc nonprofit extraction municipal source well organization dedicated protecting enhancing quantity water demand necessary conduct wildlife habitat whc help large landowner operation data begun track united state manage unused land water conservation index quantity ecologically sensitive manner benefit wild water intake divided quantity water life certifies site meet stringent require demand index indicates degree ments habitat enhancement facility reuses water internally meet total de mand lower index internal reuse lillys whccertified tippecanoe laboratory site occurring facility lafayette indiana includes 1486 acre farm land 607 acre managed wildlife beginning 2004 calculated water conserva 100member wildlife habitat team made tion index site water intake exceeding employee retiree family numerous 200000 liter per day 53000 gallon per day community volunteer team project include represents 12 lilly site worldwide prairie restoration tree shrub planting site five reported index less 01 2004 terfly garden nest box placement monitoring mean take less one liter bluebird house wren walking trail water every 10 liter actual water demand help promote awareness environmental issue needed operation result show effort enhance property bulk manufacturing site well conserving water striving im provements 26 protecting health safety environment 750 elementary middle school high logical preserve focusing reintroduction native school student use tippecanoe laboratory plant implementation began 1994 plant site every year whcs corporate land ing 5000 tree 5acre area including learning program addition six school 20 variety tree incorporating walking purdue university use area outdoor lab trail information sign also maintain including school agronomy entomology chard wild grass area attracts native insect environmental science forestry horticulture butterfly lilly also provided information environmental engineering program allows company interested establish student age engage activity designed wildlife area site teach variety habitat historical resource follow walking trail erl wood facility conservation management prairie observing specie bluebird wood erl wood england duck heron beaver team lilly scientist lillys rd center erl wood joined hand teacher community environmental leader local wildlife trust gain greater understanding developed curriculum allowing student perform 47acre site surrey england established experiment site return classroom institution area trust vast experience analyze data local knowhow managing nature reserve site interest collaborative effort 2005 initiated longterm relationship developing conservation management strategy tween usda forest research center tippe site besides habitat preservation site en canoe laboratory forest plantation installed hancements planned provide lilly employ 5acre parcel purpose developing ee opportunity explore site nature improved genetic trait hardwood specie walnut trail guided walk environmental challenge day butternut project last least 15 year winwin situation research center initiative since lilly site located two mile new biodiversity project include 15acre purdue campus research location wildlife habitat greenfield facility located 100 mile away constructed 2006 done part facility stormwater management plan also lilly arbor project indiana u 2007 150 acre riparian vegeta lilly foundation continues support lilly tion established along wabash river clinton arbor project initiative center earth facility environmental science indiana university purdue university indianapolis arbor emission effluent waste acronym answer restoring bank climate change greenhouse gas emission river primary goal develop outdoor issue global climate change increasingly research experiential learning site teaching important stakeholder business principle sciencebased environmental steward public concern policy create risk opportuni ship part longterm project faculty tie associated greenhouse gas ghg emission student community volunteer including many lilly employee worked together plan track direct indirect ghg emission implement monitor reforestation 85 acre operation including manufacturing nonmanu riverside corridor along white river facturing facility wastewater treatment plant town indianapolis indiana u employee air travel indirect emission compose 70 percent total ghg emission repre lilly development centre montsaintguibert sent quantity ghgs emitted offsite electric belgium utility energy provider service provider since acquiring 11hectare research site bel engaged activity behalf activity gium 1993 lilly worked diligently enhance include habitat improve specie diversity portion electricity generation property maintained wildlife steam generation partnership local university catholic uni chilled water production versity louvainlaneuve conservation scientist offsite waste incineration worked lilly plan biologically diverse eco wastewater treatment publicly owned treatment work potws 27 protecting health safety environment 80 percent lillys ghg emission ozone depleting substance direct indirect result energy use actively phasing use ozonede set goal achieve onethird reduction en pleting substance still present ergy intensity corresponding ghg emission heating cooling refrigeration equip operation 2010 compared 2003 baseline ment 2005 emission ozonedepleting sub part initiative improved data stance nearly zero reduction 98 percent collection developed energy policy created compared 2004 10 million annual capital fund energy waste reduction project 2003 2005 energy usage increased 2 percent sale grew 16 percent translated 13 percent reduc tion ghg emission intensity thousand kilogram co2equivalent emission per million dollar sale demonstrating progress toward reduction goal active participant climate resolve responsible environmental step opportunity lead voluntary effort initiative involving america largest company aimed volun tarily controlling emission ghgs linked global warming business roundtable developed cli sulfur emission mate resolve response u president bush sulfur oxide acid gas precursor contrib challenge business community voluntarily ute acid rain formation reported term reduce ghg intensity 18 percent 2012 lilly sulfur dioxide so2 acidity equivalent lilly company participating program acidification pollutant mainly sulfur dioxide pledged seek innovative costeffective so2 nitrogen oxide nox air emission method mitigating ghg emission foster compound result primarily fossil fuel ing continued economic growth combustion steam production manufactur ing site 2005 so2 emission declined 15 percent total 19 percent normalized sale compared 2004 expect so2 emission continue decline 2006 decline significantly 2007 several site convert lower sulfur fuel including one site plan replace coalfired boiler natural gas unit 28 protecting health safety environment u agency honor tippecanoe laboratory clean air award air quality program improved produc usenables plant implement process tivity tippecanoe laboratory received national equipment change without extensive idem per recognition early 2006 epa honored mit review change 2005 program diana plant flexible air permit clean air ex saved company idem 1000 cellence award regulatorypolicy innovation hour permit development review time category tippecanoe management corporate project delayed due permit process environmental affair partnered indiana department environmental management idem permit also simplified compliance manage develop permit based site ment consolidating overlappingand sometimes using emission control continuous emission inconsistentrequirements allowing environmental monitoring system exceed state federal staff spend time working improvement regulatory requirement site environmental management system waste minimization effort permit applying stateoftheart technology enhanced lillys ability respond everchanging foreseeable change fiveyear period market demand product produc permitone flexible permit tivitydriven change solvent emission emission continue decline due factor cited lilly us solvent wide array activity discontinuation process laboratory pilot plant manufacturing opera historically used large quantity tri chemical tions vast majority solvent emission occur bulk scale manufacturing site indi wastewater ana significant source solvent emission majority lillys wastewater greatest equipped stateoftheart emission control amount total chemical oxygen demand cod system many location use formal leak detec facility discharge directly surface water tion repair program find repair small come three bulk pharmaceutical manufacturing leak solvent vapor furthermore many location indiana u ireland indiana manufacturing process equipped recover manufacturing plantsclinton laboratory reuse solvent determined effective tippecanoe laboratoriesdischarge wabash way measure progress minimizing solvent river permit issued indiana depart emission express loss percent solvent ment environmental management discharge used believe target 1 percent loss plant significantly allow percent use nearing industry best practice able discharge limit total cod kinsale 2004 2005 exceeded target mini ireland plant operates integrated pollution mizing solvent emission percent use less prevention control license issued irish 05 percent epa 2005 discharge kinsale harbor subset solvent emission air reportable 2005 water discharge average average daily permit limit toxics release inventory tri require data site discharge flow cod total ments united state seen air clinton 778 mgd 625 lbday 15559 lbday tippecanoe 840 mgd 1438lbday 14025lbday kinsale 03 mgd 290 lbday 9900 lbday lbday pound per day mgd million gallon per day longstanding commitment monitor biological diversity wabash river kinsale harbor lilly cinergy corporation regional electric utility also discharge wabash jointly funded river study 30 year 29 protecting health safety environment also commissioned longterm study kinsale harbor located along southern coast ireland study begun 1978 searcher national university ireland galway recently completed monitoring result sug gest minor change observed aquatic life kinsale harbor associated natural stress storm event rather dis charge effect facility overall ecologic system harbor shown high measure resilience ability thoroughly disperse wastewater discharge waste generation management adopted corporate goal realize one third reduction purchase hazardous materi al percentage sale 2010 inno vative process facility design consistent corporate waste management policy adopted additional internal goal reduce waste generation although two approach desired result samereduce amount waste generate result operation plan achieving goal three mean 1 using green chemistry page 24 assist design manufacturing process reduce number kilogram waste generated per kilogram product made 2 increasing solvent recovery reduce amount solvent waste created manufacturing 3 continuing use waste minimization plan site drive reduction everything paper production waste waste minimization multiplying effect generate saving across lilly business generate safety environmental improvement inside outside company boundary compared 2004 2005 solid waste generation declined 7 percent total 12 percent normal ized sale waste recycling declined 1 percent beneficial reuse byproduct pro corporate environmental affair group coordi duction process rose 35 percent 28 percent nates conduct review commercial waste normalized sale management facility u puerto rico verify operated environ beginning 2005 reporting waste genus mentally appropriate manner site outside u tion management using category developed conduct review commercial waste manage pharmaceutical industry believe ment facility use following corporate provides u useful information manag procedure frequency review based ing waste upon type service supplied 30 protecting health safety environment example incinerator hazardous nonhaz comprehensive environmental response ardous reviewed every three year non compensation liability act commonly known hazardous waste landfill reviewed every five superfund designated one year review may involve site visit several potentially responsible party respect reviewing team observes operation examines docu fewer 10 site superfund respon mentation interview facility personnel sible party may jointly severally liable entire amount cleanup also continue compliance liability remediation certain site ac crued estimated superfund cleanup cost remedi effort reduce number accidental release ation certain environmental matter tak environment showed continued success 2005 ing account applicable available information number reportable accidental release world regarding site condition potential cleanup method wide dropped 5 2004 2 2005 estimated cost extent party significant enough reportable respective expected contribute payment government agency none release resulted cost reached settlement liability identifiable threat human health insurance carrier providing coverage certain environment one goal remainder environmental liability decade achieve level zero serious envi ronmental event committed making health safety environmental hse consideration priority fine monetary penalty imposed new product development manufacturing government agency 2005 necessitates identifying managing risk evalu ating potential hse impact operation product well hse capability supplier thirdparty operation compliance performance summary 2001 2002 2003 2004 2005 environmental fine 1 2 2 1 0 environmental fine u dollar amount 3000 17000 71392 18000 0 reportable accidental release 14 14 12 5 2 health safety fine 0 0 0 1 0 health safety fine u dollar amount 1479 0 environmental audit lilly facility 7 5 12 13 14 health safety audit lilly facility 6 9 14 16 16 beginning 2002 environmental audit lilly facility joint health safety environmental audit 12 joint audit conducted 2003 13 2004 additional health safety audit 4 2002 2 2003 3 2004 2 2005 represent process safety management audit 31 key issue ethical marketing use lilly dedicated discovering developing canada germany u uk see box novative product improve health well lillys regional head europe middle east people around world introduce africa plus many lilly general manager medicine market believe address also involved european federation unmet patient need product approved pharmaceutical industry association pharmaceu use market compliance code tical research manufacturing association business conduct company policy applicable local area working group effort strengthen requirement closely monitor result medi regional code cine enters widespread use marketing pharmaceutical informs health care lilly lead push strengthen uk pharmaceutical code provider patient availability medicine benefit risk potential ethi late 2004 association british pharmaceuti cal issue arise however interaction cal industry abpi began process update code pharmaceutical company representative purchas practice governs industry relation er prescribers user medicine addition health provider stakeholder lillys managing regulation norm concerning marketing director uk selected chair effort pharmaceutical vary worldwide creating complex context promote product public consultation independent market also growing public concern cost medi research abpi engaged dozen organization individual representing patient advocacy group cines see pricing pharmaceutical page 35 consumer group professional body regulator related issue drug reimportation counter public sector industry consultative process feiting see statement key issue page 53 revealed area improvement existing code practice relied industry selfregulation backed case litigation arisen lilly product strong role regulator see product liability issue page 35 promotion al practice see product promotion issue page 36 based consultation abpi adopted change code signed memorandum understanding governance product promotion regulatory body among element lillys code business conduct red book applies memorandum encourages medicine healthcare employee worldwide requiring display product regulatory agency mhra review promo tional material new pharmaceutical product proper business conduct avoid conflict interest use also acknowledges mhra act comply law protect company asset needed selfregulation fails red book cover wide range business practice high level including pharmaceutical promotion key change code include requirement interaction health care provider lilly printed promotional material include prominent infor employee receive code business conduct training mation report adverse drug reaction limit must certify comply code advertising promotion pharmaceutical red book publicly available investorlillycom step accelerate process assessing complaint downloadslilly_red_book_publicpdf decision made quickly sanction imposed faster red book draw detailed confidential lilly policy based company value law regulation industry code conduct varying requirement market applicable lillys policy local law differ operate lilly affiliate local busi lilly employee held higher standard ness unit work company global mar keting compliance department develop local lilly involved sometimes led ef marketing promotion policy andor standard fort create industry code conduct example operating procedure consistent principle south america middle east update stated red book well applicable internal improve existing standard used external requirement voluntary commit ments ensure compliance affiliate pol 32 ethical marketing use icy lilly comprehensive sale marketing care health care delivery review grant compliance program includes oversight train recipient also undertaken prevent undue ing selfassessment audit incentive sanction influence prescribing purchasing registration remediation see figure c reimbursement lilly product input gift payment nothing value may given industry code lilly code legal offered health care provider unduly global business conduct requirement regional national influence decision regarding lilly prod regional lilly global policy national local ucts affiliate must establish document monetary limit value gift may affiliate local policy provided provider accordance local law regulation policy procedure industry professional code ii implement system track payment service health care provid er subject annual limit communication training monitoring incentive meeting hospitality scientific educational auditing disciplinary action objective must principal focus lilly funded meeting program whether promo compliance support tional medical scientific independent nature educational activity must account majority figure c comprehensive sale marketing compliance program total time spent event meeting time limit apply hospitality entertainment activi affiliate policy must consistent follow tie also limit acceptable venue ing sale marketing principle devel meeting avoid lavish setting oped summarize lillys global policy provide guidance employee partnering external organization local com pany policy reflect following key principle sale marketing activity affiliate interaction external organization pa principle policy address tient advocacy group professional association buy business charitable donation gift payment educational grant side must work together equal partner meeting hospitality promote best interest patient partnering external organization company must attempt oblige external group conform marketing agenda ex promote offlabel promotional educational use approved promotional material review process change funding educational material consumer communication company funding andor sponsorship external follow sampling rule product sample distribution group initiative must made public explicit disguise discount must written understanding report adverse event patient pharmaceutical party establishing type relationship product complaint safe data use expectation side always protect data privacy respect privacy company must encourage external organiza tions diversify funding lilly personally accountable compliance lilly brand dominant financial source company avoids creating external organiza tions focus instead helping existing orga charitable donation educational grant nizations develop grow affiliate must specify charitable request received processed evaluated approved com promotional educational material review municated process managed department process distributed custom outside sale marketing applies preestab er promotional material must reviewed lished criterion evaluate request priority giv local medical regulatory personnel accordance en potential improve patient local procedure establishes review criterion consistent lillys global standard well local law regulation code conduct 33 ethical marketing use consumer communication patient seeking sponsible compliance reporting require information disease treatment ments allowing u meet commitment asking question evaluating information mak safe use product ing choice believe patient access information medicine variety employee required report within one busi source including pharmaceutical industry ness day adverse event product quality com committed providing accurate truthful plaint andor suspected counterfeiting diversion balanced information communica tampering involving lilly medicine device tions including consumer marketing advertis especially important lilly personnel inter ing effort demonstrate commitment act directly health care provider every day 2001 adopted principle directtoconsumer communication updated 2005 reflect affiliate must develop procedure ad pharmaceutical research manufacturer verse event reporting required regula america phrma code strengthened tory quality system rqs consistent principle 2006 page 36 reporting requirement stated red book product sample distribution affiliate dis respect privacy eli lilly company tribute product sample must policy operated global privacy program since 2001 procedure consistent local legal requirement privacy program led lillys chief privacy officer governing control accountability sample cpo global responsibility privacy distribution storage sample within appropri compliance cpo report law division ate temperature range appropriate approval well chief compliance officer chief package modification information officer lillys cpo 20 fulltime privacy employee 300 global privacy steward make patient pharmaceutical safety data use lilly privacy program among strongest corporate strong commitment understanding com america lilly used position influence municating safety product clinical company including establishing chairing trial designed identify potential safety issue international pharmaceutical privacy consor medicine approved effort continues tium comprised 15 largest pharmaceuti bring approved medicine market cal company establishing one first privacy long used investment audit function one first vendor privacy safety global ongoing collect store certification program implementing privacy self single database information around world assessment globally across company providing related potential safety issue enable fullest computerbased privacy training mandatory possible understanding safety product u employee establishing detailed tracking global network safety professional metric finally joining leading company sponsible compliance reporting require push federal consumer privacy legislation ments allowing u meet commitment u safe use product 2004 lilly initially certified euus privacy also dedicated effectively communicating safe harbor enables lilly export personal information important patient safety product information eg clinical trial patient investigator labeling provides best available data use lilly employee physician consumer data medicine doctor health care provid european union u lilly recertified er ultimately patient year since original certification affirming publicly company adequate privacy safe addition ensuring physician patient guard protect personal data originating eu latest safety information quickly safe harbor certification recognizes lillys commit possible distribute information regulatory ment handle personal information way authority worldwide within required time frame protects individual privacy right global network safety professional adheres eu privacy law lilly material privacy compliance issue 2005 34 ethical marketing use report published october 1 2003 journal pricing pharmaceutical american medical association association thimerosalcontaining vaccine au pharmaceutical price along health tism medical researcher concluded found care cost rising many part evidence association thimerosal world raising concern among stakeholder containing vaccine autism child com cost medicine pared child received vaccine formulated without thimerosal largest many factor affect price consumer pay scientific study date based review pharmaceutical including manufacturer 467450 danish child wholesale price wholesaler pharmacist markup patient insurance coverage country governmentsponsored health study released 2002 world health orga care coverage price control nizations global advisory committee vaccine safety university rochester medical price product mindful dual responsibili center also confirmed safety thimerosal tiesto realize profit enable u university rochester study researcher invest discovery next generation found ethyl mercury kind mercury novative medicine permit patient thimerosal halflife blood access value innovative medicine 7 day versus methyl mercury halflife 45 bring family today day quick elimination suggests ethyl mer cury would accumulate body according appropriate patent protection society researcher vaccine safety institute create incentive pharmaceutical compa ny develop innovative new medicine lilly understands autism devastating di believe rewarding pharmaceutical innovation agnosis family end want everyones interest however high price ensure science politics find cause new medicine present barrier autism best possible treatment might benefit developed hopefully cure emerging market take issue serious ly following section discus zyprexa step taking expand access medicine beginning early 2003 product liability case filed lilly claiming antipsychotic addition launched major effort medication zyprexa caused patient variety lower overall cost bringing drug market injury case allege zyprexa improving efficiency throughout value chain also exploring new model developing caused diabetes high blood glucose level delivering tailored therapy type litigation included manufacturer use technology biomarkers pharma atypical antipsychotic risperdal cogenomics bioimaging better predict seroquel therapy effective pa tients ensuring patient receive better value since june 2005 lilly entered agreement medicine use achieving goal various claimant attorney involved u right drug right dose right time zyprexa product liability litigation settle large number claim firmly believe lawsuit zyprexa supported product liability issue scientific evidence business decision enter thimerosal agreement settle majority litiga lawsuit filed lilly tion driven desire reduce significant manufacturer claiming link uncertainty involved litigating complex vaccine preservative thimerosal autism stud case settlement agreement significant y recent 2004 continue show step helping lilly employee scientific evidence support link fact get core business also begin scientific evidence indicates exactly opposite remove physician told u barrier confidence making best treatment deci sion individual patient need pre 35 ethical marketing use pared continue vigorous defense zyprexa disease condition often undiagnosed remaining case untreated undertreated company responsible developing new innovative medicine question arisen whether stand duty provide advertising increased risk diabetes patient take truthful accurate balanced end zyprexa important note compared established following principle help serve general population patient serious mental guide designing launching dtc commu illness substantially greater rate diabetes 2 nications principle initially adopted 4 time greater available data support 2001 revised reflect august 2005 causal link zyprexa diabetes since zy phrma guiding principle lilly dedicated fully prexa introduced 1996 prescribed abiding spirit principle well 19 million people worldwide principle 2003 fda informed sponsor marketed 1 allow sufficient time educate physi atypical antipsychotic medication product cians healthcare professional label updated concerning diabetes ad lilly medication advertising verse event agency recognizes relation public based specific factor vary dis ship atypical antipsychotic use hyper ease state including complexity risk glycemiarelated adverse event completely benefit profile health care professional understood epidemiological study sug knowledge condition treated gested increased risk end 2004 manufacturer complied request 2 involve patient health care profes sionals advertisement development process product promotion issue obtain perspective input regarding december 2005 lilly reached settlement dtc campaign also involve general u government investigation evista public appropriate marketing promotional practice company agreed plead guilty one misdemeanor charge 3 adhere fda standard regarding dtc offlabel promotion evista 1998 campaign submit new tv product cam paid penalty 36 million deeply regret paigns ddmac prior broadcast give 1998 conduct resulted federal misde fda opportunity comment includes meanor charge take seriously responsibili creating product advertising provides clear ac tie abide law governing business curate responsible information fair practice committed ensuring em balanced benefit risk associated ployees action reflect highest legal ethical medication clearly identifying condi standard conduct although government tion prescribed end charged lilly unlawful intent longer air broadcast reminder ad continue take step designed assure lillys exception sponsorship promotional activity remain fully compliant 4 knowingly create advertising con information available wwwpmcpaorguk tains false misleading exaggerated unbalanced statement visuals utilize creative de lilly principle directtoconsumer sign respect seriousness health condi communication tions medicine advertised given increasingly complex health care system know patient seeking informa 5 create dtc campaign reinforce tion disease treatment asking question physicianpatient relationship encouraging pa evaluating information making choice tients seek additional information guidance believe directtoconsumer dtc advertising health care provider provides many benefit including raising awareness 6 protect confidentiality patient infor mation generated dtc campaign 36 ethical marketing use 7 advertise way encourage appro priate use product include informa tion availability option diet lifestyle change appropriate advertised condition 8 target advertising directly individual age eighteen 18 design medium plan achieve 80 percent adult audience level 90 percent cialis avoid audience ageappropriate message involved 9 place advertisement medium envi ronments avoid controversial contentpro gramming respect diversity align company value 10 spirit answer matter provide customer feedback mecha nisms express opinion dtc campaign 37 key issue access medicine throughout world patient concerned lillyanswers access medicine need today lillyanswers launched 2002 bridge pro may need tomorrow underlying issue affect gram address concern senior citizen ing access medicine differ among country faced rising medical expense lacked prescrip region world tion drug coverage lillyanswers eligible4 patient provided 30day supply lilly u approximately 45 million american retail drug monthly administrative fee 12 currently lack type health care insurance 2005 lillyanswers 235000 member pro many others limited coverage vided prescription valued 192 million uninsured cost medical treatment pre scription drug may obstacle getting care early 2006 medicare part prescription drug medicine need believe coverage introduced administered greater access affordable health care coverage permanent measure provide senior greater would expand pool people access affordable comprehensive phar insured help reduce health care cost maceutical coverage lilly recognizes patient american new prescription drug benefitmedi enrolled medicare part plan may still care part dis important step toward end experience gap coverage access needed one lilly strongly supported medicine explored best way help patient manner complies legal part world price medicine issue associated providing assistance indi one factor prevents people obtaining viduals enrolled federally funded program needed treatment developing country result lilly taking several action issue present access barrier among capacity efficiency country health care patient enrolled part plan system distribute dispense medicine abil ity provide accurate diagnosis availability extending lillyanswers december 31 2006 preventative followup care certain qualifying patient retail product patient enrolled lillyanswers europe largest segment popula december 31 2005 enrolled medicare tionthe baby boom generationis quickly ap part plan eligible patient must certify proaching retirement age trend change enrolled medicare part plan ratio retiree worker could place strain going forward new patient enrolled government funding pharmaceutical innovation lillyanswers well threaten longterm sustainability universal health care system served europe certain patient enrolled part plan an year creating new outside part program pharmaceutical company criticized program lillymedicareanswers patient enough make medicine ac enrolled part plan taking growth cessible affordable patient around world hormone certain lilly injectable osteoporosis mission develop innovative medicine antipsychotic medication patient meet save enhance life fulfilled patient eligibility requirements5 obtain 30day cannot access product therefore company supply drug administrative fee strongly committed philanthropic pa 25 seeking advisory opinion tient assistance program designed provide greater u department health human service access lillys medicine office inspector general oig regarding appropriate implementation new outside increasing access medicinesunited state part patient assistance program lilly donates product various patient assistance program currently offer six program 4 usually individual medicare eligible u citizen uninsured u 2005 helped 410000 annual income fall 200 percent federal poverty patient obtain needed medicine addition level 5 addition meeting eligibility requirement enrollment following patient assistance program participate lillyanswers certain patient enroll proposed lillymedicare access program 26 state answer program must provide documentation 38 access medicine providing bridge benefit current lillyanswers increasing access medicinesinternationally patient qualifying patient lillys marquee global access program lilly mul enrolled medicare part plan prescribed tiple drug resistant tuberculosis mdrtb program certain lilly injectable osteoporosis antipsychotic discussed detail addition lilly medication bridge benefit available supporting number corporate local initiative new outside part program imple aimed making medicine available mented date lilly may deter improving patient outcome mine multidrug resistant tuberculosis partnership lilly care 2003 lilly launched 70 million global initiative lilly care foundation provides number address rising incidence mdrtb strain free medicine physician qualifying u tb infecting estimated 400000 people year patient eligibility based patient income notably china india africa former soviet must less 200 percent federal union known lilly mdrtb partnership poverty level lack thirdparty drug coverage multipronged crosssector initiative involves 14 2005 lilly care served 176000 patient medica partner focused three way transferring tions valued 197 million lillys proprietary manufacturing technology enhanc ing disease surveillance training program partnership prescription assistance increasing supply capreomycin cycloserine lilly participates partnership prescription medication effective treatment mdrtb assistance ppa program brings together america biopharmaceutical research company technology transfer health care provider patient advocacy organization ongoing transfer lilly drugmanufacturing community group help qualifying patient expertise mdrtb medicine capreo without prescription coverage obtain medicine mycin cycloserine company india china free nearly free ppa offer single point access russia south africa increase global supply 275 public private patient assistance product lower cost funding program including 150 program offered lilly expert purdue university training sci pharmaceutical company entists plant manager company manufacturing skill good business practice access program lilly three targeted program assist patient shasun chemical drug india validated obtaining specific medicine include manufacturing cycloserine dispatched first order february 2006 lilly oncologyassists patient obtaining reimbursement gemzar alimta hisun pharmaceutical china validated manufacturing capreomycin hisun provide xigris treatment support programassists active pharmaceutical ingredient api aspen certain healthcare institution provided ur pharmacare produce final form gent potentially lifesaving treatment patient drug hisun also working expansion insurance capacity pay facility locally produce final form capreomycin ensure longterm success humatropeassists patient obtaining full manufacturing partnership lilly committed partial supply medicine also provides provide technical assistance necessary training support health care professional reim bursement center aspen pharmacare south africa sold first batch cycloserine botswana late 2005 plan information patient assistance program start making cycloserine new facility many found online wwwlillycom 4 billion capsule per year aspen began construc tion another facility produce capreomy cin vial 39 access medicine sia international russia lillys newest manu international hospital federation ihf facturing partner may 2006 expects working comprehensive tb mdrtbcon making cycloserine late 2006 trol training manual hospital manager distributed ihfs 40000 public private prevention treatment surveillance training hospital clinic member lilly belief key stopping spread mdrtb greater public awareness adequately u center disease control cdc de trained health care worker ensure proper veloping cuttingedge laboratorybased electronic diagnosis treatment availability ef surveillance system russia monitor patient fective medicine 2005 continued make resistance mdrtb drug new information progress along line example management system may used country standardize tb mdrtb data col lillys support 2003 harvard medical lection analysis method school partner health pih established center excellence tomsk russia 2005 effort concert world health doctor nurse health care worker organization stop tb partnership former soviet union trained organization supporting close prevent detect treat tb mdrtb addi 40 country effort establish strategy tion russian version pih guide mdrtb management provides needed medical management mdrtb published technical assistance country analyzing mdrtb advisory board established caseloads treating patient developing na bringing together multiple party work tional program within whoapproved treatment corporating mdrtb protocol russianbased guideline also monitor trend global tb center excellence pih working resistance firstline tb drug assessment five tuberculosis research institute russia carried china india russia several development national mdrtb training country order strengthen mdrtb control standard practice international federation red cross red increasing supply medicine crescent society fund lilly developed transfer technology lilly increas mdrtb awareness outreach program ing supply critically needed antibiotic implemented country former also support world health organization dot soviet union eastern europe plus program directly observed treatmentshort course mdrtb patient providing world medical association lilly work mdrtb drug highly discounted price since ing together craft mdrtb internet training launch initiative doubled quan course doctor tity drug provide international council nurse icn believe lilly mdrtb partnership lilly working develop training guideline improve health care worldwide establishing nurse detection treatment management lasting model bringing public private organi disease icn also launched tbmdrtb train zations together fight pandemic epidemic ing trainer pilot program nurse south africa extended philippine additional information lillys partnership history initiative available online world economic forum wef tested pilot wwwlillymdrtbcom program india aimed building awareness workplace tbmdrtb particular fo cu detecting early sign infection identi fying go diagnosis treatment program received support lilly implemented india 2006 promoted globally wef corporate member 40 access medicine publicsector need medicaid pharmacy partnership program mhmpp lillys commitment innovation patient care made available missouri medicaid pre make u valuable partner publicsector payer scriber identify inappropriate inefficient medicaid actively seek provide use behavioral health medication within need customer able offer variety medicaid system mhmpp us nationally accepted resource improve patient care financial guideline clinical practice identify inappro outcome public health sector best address priate inefficient prescribing physician public health need lilly established business identified educational communication aimed togovernment organization 2002 organi changing prescribing behavior benefit zations mission align lilly resource help mhmpp include increased adherence clinical publicsector customer achieve optimal balance practice guideline evidencebased practice quality access cost care patient lead potentially superior clinical use publicsector health care program important outcome first full year partner component mission include partnering ship state medicaid program saw decrease state medicaid agency disease management 98 percent number patient patient care quality improvement project tailoring prescribed mental health medicine patient assistance program meet local health multiple doctor 43 percent reduction care need working unrestricted access number child take three psycho medicine people mental illness tropic medicine program allowed missouri save 77 million taxpayerfunded medicaid cost developed partnership many state local health care authority past three based initial success missouri lilly year support businesstogovernment mi actively partnering 15 state mhmpp sion key program type highlighted including state utah january 1 currently fully implemented pro 2004 august 31 2005 number utah gram 30 state patient prescribed multiple medicine multiple prescribers decreased 74 percent addition since 2001 lilly working ar number patient prescribed two kansa medicaid agency disease management atypicals also decreased 74 percent result initiative focus intensive patient educa pharmacy spending lower expected tion program people diabetes arkansas diabetes control program patient continue learn project taught weight body mass index blood best meet need publicsector customer pressure high hemoglobin a1c level affect patient serve disease participant receive detailed guid ance blood glucose monitoring foot care health behavior program resulted measurable reduction depression blood pres sure blood sugar level disease compli cation among participating patient well reduction diabetesrelated cost since inception concurrently lilly partnered arkansas significantly improve infrastructure diabetes treatment established 12 american diabe te associationaccredited education center across state effort help state medicaid department manage pharmaceutical spending without restrict ing patient access appropriate medicine lilly established pilot partnership state missouri 2003 missouri mental health 41 key issue investing community lillys history philanthropy trace back 1906 helping patient mental illness provided disaster relief san fran lilly committed fight stigma cisco earthquake year built tradi mental illness improve life tion giving back local community around mental illness family world particular focus example lillys effort 2005 improving patient outcome providing access lilly spain partnership spanish psychi lilly medicine see atric society mental health advocate supporting scientific education research created wellness program called whole life page 43 get better program combat social stigma providing disaster relief page 44 discrimination toward mentally ill showing encouraging employee involvement page 45 people mental illness may integrated society enhancing life com 2005 lilly contributed 511 million munities lilly spain contributed 600000 euro global philanthropy highest yearly total phil us750000 wellness program anthropic donation company 130year histo ry 453 million u net wholesale price lilly belgium continued fund project help donated product patient assistance program individual suffering mood andor thought international humanitarian cause remain disorder reintegrate society independent ing 58 million donated cash contribution panel psychiatry expert selected three project company lilly foundation receive lilly reintegration award 2005 total total contribution represented nearly 13 percent 15000 euro u 18750 one award went adjusted earnings tax 35 percent rev job program strives broaden employment enue making lilly one charitable compa opportunity suffering mood andor ny u thought disorder lilly germany sponsored award program 2005 philanthropic donation past three year recognize public servant helped destigmatize mental illness 2005 independent jury awarded mutprize coura geous action dr regina goerner former minister health social affair saarland state 58 million cash contribution southwest germany goerner recognized 453 million donated product initiating nationwide virtual workshop enabled mentally ill citizen participate labor market lilly canada committed 2 million two year launch lilly neuroscience solution wellness educational fund goal support innovative program aimed enhancing wellness patient facing mental illness improve qual improving patient outcome ity life better manage complication u country lilly affiliate disease combat stigma mental illness located various initiative launched currently 30 program across canada received help improve outcome patient experience relat grant amount 100000 ed key therapeutic area including neurosci ence diabetes cancer 2005 report focus lilly czech republic provided 45000 zme lillys effort improve outcome patient na change initiative address social mental illness stigma discrimination associated mental illness seek transform delivery mental health service czech republic 42 investing community lilly turkey helped create outpatient facility knowledge lillys methodology help improve istanbul specializes serving patient suffer telethons internal process shorten time ing schizophrenia inner garden day hospi frame newly discovered treatment rare dis tal officially opened april 2006 received eas reach market begin benefiting patient 100000 support lilly turkey facility offer medical treatment counseling host lilly france established institut lilly 1990 therapeutic rehabilitative service continually funded collaborative endeavor schizophrenia patient family lilly tur purpose supporting clinical research key employee supported inner garden offering training health care professional book drive fill empty shelf pa informing patient 2005 institut lilly partnered tient library company matched employee effort estee lauder company inc support additional cash donation breast cancer prevention awareness campaign breast cancer let speak support helping child diabetes instrumental getting 200 informational life child diabetes program operated display breast cancer awareness doctor international diabetes federation idf aim pharmacist bringing together oncologist bring insulin medical service child patient talk preserving quality life adolescent type 1 diabetes lilly continued battling breast cancer publishing 10000 infor partner rotary international international mative pamphlet woman going treat service organization help finance life child ment since inception institute provided fund contributed lilly employee spur lo 250 research grant trained 90000 medical cal rotary club raise additional fund professional matched rotary foundation lilly usa also support number sciencerelated 2005 lillys contribution totaled 82000 achievement including helped provide treatment support 530 child living 11 developing country including lilly host teacher day twiceyearly event child tanzania first time plan provides local science teacher opportunity place reach child nigeria nepal load cart full free lab equipment recovered program 2006 lillys research facility 2005 donated 80 pallet equipment worth 120000 supporting scientific education research teacher use classroom local school advancement science special focus university lillys community investment ex amples multilevel approach support science education research teacher day donation lilly uk teamed education consortium lance brand high school science educator recipient organize step science event geared toward 2005 milken national educator award seen local secondary student basingstoke event teacher day donation benefited student featured workshop aimed enhancing student current budget situation school doesnt coursework introducing activity allow purchase much equipment let make science come life alone expensive research equipment allows student explore field biotechnology biotech lilly italy completed second year three nology activity exciting student give year partnership telethon renowned italian research foundation lilly providing 100000 euro sense real science modern world us120000 annually fully fund two telethon like without donation lilly scientist selected spend year activity wouldnt even possibility lilly italy medical division receive specialized mr brand said training scientist use newly acquired 43 investing community lilly offer variety scienceoriented distance red cross donated 3 million learning program virtually reach medicine addition lilly matched dollarfordollar classroom world equipped distance employee contribution nearly 500000 learning capability program also engages lilly employee volunteer share early 2005 lilly donated 2 million knowledge experience participant dur cash relief agency help victim cata ing 2005 program reached 2770 participant strophic tsunami late 2004 working 75 site catholic medical mission board cmmb lilly also donated antibiotic treat 60000 patient lilly foundation made 75 million grant 2005 indiana university cancer center following massive earthquake kashmir premier clinical research institution fund region pakistan lilly worked cmmb used recruit nationally recognized cancer international medical corp airlift urgently scientist strengthen research initiative needed medicine supply valued 2 million affected community providing disaster relief 2005 devastating natural disaster took toll hurricane stan struck part central america number region around world october 2005 causing severe mudslide guate example type relief support lilly provided mala destroyed mayan village area resident started little working immediately following hurricane katrina lilly project hope lilly donated 200000 helped victim affected area making cash product shipped february 2006 contribution 1 million ameri hurricane relief personal way hurricane katrina struck devastating force august 2005 destroying home business community along u gulf coast one town particularly hard hit bay st louis mississippi hometown jim collins executive director eli lilly company soon hurricane passed collins personally committed helping relief effort inquired whether lilly could provide support answer immedi ately yes next morning lilly response team took action way collins described going beyond donation money material personal cor following hurricane katrina lillys response team delivered critically porate relief effort midafternoon collins needed medicine supply affected area two occasion two colleague robert reilley dr greg larkin second trip team consisted left bob reilley dr greg headed southwestern mississippi corporate larkin jim collins steve huckstep jet filled needed medicine supply received ontheground support u coast time stayed week help coordinate local medical guard ensuring precious cargo delivered relief effort recognizing impact effort location storm victim assisted local community collins sent message back lilly headquarters presence brief time mississippi convinced support pharmaceutical product sponse team significantly help much appreciated affected communi needed two week later returned missis tie im extremely proud part company sippi additional medicine supply truly committed helping time need 44 investing community encouraging employee commitment lilly usa employee also dedicated time lilly encourages employee play active role resource strengthen community many community charitable giving way lilly headquarters central indiana volunteerism 2005 lilly employee around employee world demonstrated commitment build stronger community example include worked 1700 hour nonprofit organization habitat humanity build two lilly brazila team nearly 250 lilly employee home near lilly facility indianapolis sup service provider family member partner port effort lilly contributed 120000 organized hosted health citizenship day towards project november 2005 estimated 3700 member povertystricken community city sao paulo tutored local school child reading reporting attended event provided classroom time week critical information health personal hygiene hour throughout school year well glycemia blood pressure testing donated fund united way charity lilly mexicothe lilly mexico foundation matched contribution lilly founda recently created support local social development tion total 92 million lillys giving rep program lilly employee encouraged par resented approximately 25 percent central ticipate shared action program employee indiana united way 2005 campaign volunteer program employee also propose organization volunteer receive financial support foundation 2005 lilly mexico foundation provided 4 million cash contribution 820000 product donation lilly egyptemployees joined force help fund opening new hospital dedicated care child cancer hospital type egypt ninetysix lilly employee mak ing monthly contribution hospital payroll deduction provide free service diagnosis treatment followup young cer patient well conduct research field childrens cancer lilly israelsixtyfive percent employee partici pated shekeladay giving program increasing contribution 112 percent last year program employee donate one shekel day salary community investment fund fund matched lilly sup port local afterschool program child troubled background lilly israel employee also spend many hour tutoring mentoring sup porting child 45 key issue workforce workplace responsibility toward employee lillys employment philosophy lillys employment philosophy guide practice help u achieve goal securing employment philosophy based set longterm trust loyalty commitment em fundamental belief ployees achieve higher level performance productivity believe employee nature good lillys philosophy treat employee want best company cu began founder colonel eli lilly estab tomers fellow employee lished core value respect people integrity excellence leadership passed believe employee motivated founder son later grandson commit paycheck want connected ment uphold tradition value endured work make meaningful difference still hold true today world work community colleague committed common goal 1916 report subject employment jk lilly jr grandson company founder believe principle reciprocity wrote employeremployee relationship yet also believe company carry heaviest respon without loyalty team sibility beginning relationship work higher level demonstrating employment practice output quality service leadership behavior truly believe value integrity excellence respect impossible people earn trust loyalty commit ment employee employee reciprocate productive contribution company breakdown work force missionvision commitment end 2005 lilly 42000 em ployees worldwide 2160 new hire employee embrace willingness flexible year turnover rate industry making sacrifice good enterprise average industry data obtained saratoga sense reciprocity demand loy institute alty rather intent secure people inherently give treated well jk lilly training development jr shared belief 1916 report many respect people one lillys core value assume mere providing work demonstrated many way one payment wage give right absolute continued training opportunity provide fidelity loyalty secured staff level enrich experience work loyalty rank may readily observed 2005 lilly employee around globe accrued 19 million training hour believe employment philosophy consis tent value excellence ex lilly universitya collection global training orga cuse tolerating poor performance employee nizations across companyprovides variety online course classroombased training topic ongoing responsibility continuously range technical jobspecific training improve performance meet constantly transferable skill performance management rising standard demanded competitive career planning presentation skill project man environment includes developing new skill agement result lilly employee access flexible adapt need emerg encouraged use program enhance ing business challenge personal accountability skill employability ultimately suc top performance closely interrelated cess workplace addition continued training provided supervisor assist leading people managing business 46 workforce workplace employee benefit encourage employee pursue edu lilly consistently recognized employ cation providing educational assistance program er choice u around world u tuition job careerrelated course offer competitive total compensation package work reimbursed 100 percent 5250 per benefit go beyond standard medi year undergraduate course 7000 per cal retirement program meet need year graduate course addition u employ employee philosophy provide benefit ee reimbursed 50 percent 100 market competitive industry attract fee paid nonjobrelated enrichment retain talented people skill exper course pursue 2005 547 employee partici tise necessary achieve company objective pated undergraduate coursework program 477 support longterm interest sharehold took advantage graduate coursework program er customer importantly patient another 57 employee took part personal benefit lilly provides globally include enrichment program retirementleaving service medicalhealth life disability insurance upholding human right diversity u lilly offer nontraditional pro lillys value reflect importance place di gram enhance successful workpersonal integra versity value include respect people tion flextime flex week parttime schedule worldwide integrity expects u operate telecommuting option highest standard honesty ethical behavior benefit include generous maternity leave parenting exemplary moral character excellence leave marriage leave educational leave also reflects continued desire improvement offer generous adoption reimbursement program diversity within company something value encourage employee participate one strongly encourage many volunteer program onsite convenience available u location include promoting workplace blend talent dry cleaning credit union cafeteria convenience every employee encourages different store two child development center 11week perspective approach work believe summer camp employee child 2005 workforce closely mirror multicultural paid 34 million maintain child marketplace make u better company care facility program united state achieve number key leader serve diversity leadership council led health wellbeing employee vice president global diversity key objective important u expect best council bring integration alignment employee strive give best accountability lillys diversity strategy return health coverage significantly exceeds workforce marketplace addition senior national standard employee able obtain leader diversity performance objective lilly manufactured marketed drug cost require diversity training u employee u employee receive certain medical service additional instruction supervisor cost access five onsite bulatory care facility maintained lilly service beyond workplace diversity key focus site include mammography screening effort improve patient care outcomesour gynecological exam personal lab service travel ultimate goal instance lilly made consider immunization assistance flu shot physical therapy able progress toward increasing number mi emergency care well coordination care norities participating clinical trial result workrelated illness injury nationally able better inform physician recognized free colonscreening program imple medicine help variety population mented 1995 date 5000 polyp 29 unsuspected cancer detected also building important partnership removed employee also access employee national urban league nul national assistance program provides confidential assess council la raza nclr reach diverse pa ments referral licensed mental health provid er three free visit per year 47 workforce workplace tient group 2006 lilly foundation nul internal grievance system launched multiyear health wellness educa company provides internal grievance process tion initiative aimed providing africanamericans consideration locally unresolved workplace fact diabetes chronic disease problem concern explanation griev disproportionately afflict population rate ance process including overview proce higher american addition lilly dural step provided employee handbook foundation provided funding nclr pro human resource representative available motores de salud mental project promotes employee desired assistance initial local mental health awareness underserved latino com area discussion grievance formal process munities emphasis migrant population ing unresolved grievance bicultural family intent initiative provide practical preventionrelated solution security training intervention local grassroots level ef security personnel participate ongoing exten fort address higher rate chronic disease among sive training protect employee topic covered minority population include corporate value conflict resolution professional standard conduct work discrimination harassment place additionally security personnel trained equal employment opportunity policy writ valuing diversity ensuring privacy avoiding ten implemented ensure provide equal harassment workplace employment opportunity employee ap plicants phase employment proudly uphold lilly policy supervisor human resource equal employment opportunity staff hand consultation assistance necessary policy carried correctly strict policy harassment workplace unwelcome physical verbal behavior inappropriate written material sexbased sexual harassment tolerated work place participating workplace activity commitment also carry reporting conduct harassment employee equal ly responsible reporting harassing condition report investigated confidential manner retaliatory action taken reporting employee employee required adhere principle policy referenced company code business conduct must read signed respected employee child forced labor member state international labor orga nization recognized ending commercial exploitation child must one humankind top priority yet despite international effort stop child labor million child throughout world continue work often terrible condition prevent ing child labor everyones responsibility lilly use support use child labor anywhere world fully abide child labor law standard additionally use forced compulsory labor adhere state fed eral fair labor law 48 key issue supply chain comprehensive approach corporate citizenship gender retention employee increasingly requires consider social environmen depends level diversity community tal effect business activity live well company supplier well described work effort use purchasing power promote diverse business assess environmental time believe sdd initiative health safety program supplier benefit beyond cultivating developing increas ing number diverse supplier supplier supplier diversity network diverse supplier grow strengthen lillys longstanding commitment equal oppor business help create wealth job tunity reinforced supplier diversity economic development opportunity within development sdd initiative one aspect local community way enhance quality company broader integrated diversity strategy community life aspect include multicultural marketing clini cal trial community relation corporate work lilly sdd implemented many bestinclass pro life initiative aimed increasing gram part overall initiative example promoting diversity across company global lilly established historically underutilized small business recognize value diversity add business husb coordinator collaboration building stronger relationship employee supplier diversity professional share common customer supplier investor mission developing business helping find contracting opportunity membership lillys sdd initiative focused broadening crosssection representative private indus participation minorityowned womanowned try government agency nonprofit organization diverse small business lilly larger successful minorityowned woman supplier base level reflective diverse owned firm member brings different focus business community environment stra combined form cohesive effort syn tegic sourcing effort make difficult small ergy created joint initiative resulted niche company play role sdd seek identify increased greater impact develop diverse supplier match unique capability diverse supplier portfolio another program supplier diversity pharma lilly business need ceutical forum smaller collaborative group diversity representative 15 pharmaceutical supplier learn participate lillys sup company dedicated creating greater opportunity plier diversity development initiative online diverse supplier serving pharmaceutical httpsupplierdiversitylillycom industry forum lilly helped establish late 1990s provides network member value supplier diversity openly share information benchmark best lillys supplier diversity initiative stem practice work cooperatively joint event commitment good corporate citizen benefit diverse small business serving provide everincreasing value customer pharmaceutical industry group meet formally shareholder employee community sdd quarterly basis interacts share best initiative helped u discover supplier offer practice among member ongoing basis product service term capability com petitive current pool supplier increasingly supplier diversity 2005 highlight smaller niche supplier base provide lilly spent 400 million usbased immediate tangible value lilly diverse small business supplier u puerto rico global competition talent imperative lilly sponsored executive diverse small lilly recruit retain best employee avail business participate amos tuck minority able talent pool get broader diverse business executive program dartmouth college year representing different culture race hanover new hampshire lilly continued active support national local diverse organization including board andor advisory position national minority sup 49 supply chain plier diversity council indiana business diver sity council puerto rico supplier development council indianapolis chapter national association woman business owner auditing supplier thirdparty contractor lilly relationship many thirdparty suppli er including assist development manufacturing lilly product partnering come responsibility ensure alli ance company implemented employee health safety environmental program lilly assesses supplier thirdparty operation health safety environment hse crite ria selection process throughout business relationship alliance partner reviewed using fivestage process firststage review pro vides basic understanding company envi ronmental health safety program second stage provides riskbased review related material handled supplier critical terials handle manufacturing step higher hse risk third step would include onsite visit fourth stage ensuring thirdpar ty operation necessary hse information material lastly track performance ac cording several metric like governmentreported data lilly encourages supplier build neces sary hse capability addition hse performance use suppli er product lilly reviewed possible health safety environmental issue lilly member u epa green supplier network forum pharmaceutical sector forum promotes identification environmental issue affect business performance supplier lilly belief supporting goal supplier continually improve environmental performance result improved business hse performance party part hse criterion lilly requires key supplier alliance partner company appropriate emergency management capability ensure business continuity addition alliance partner reviewed annually safety environmental compliance performance 50 key issue public policy lilly committed participation political al application biotechnology bio member work process responsible corporate citizen help benefit mankind expanding boundary inform debate united state health science care pharmaceutical innovation lilly operates highly competitive regulated industry business roundtable business roundtable therefore considers participation political association chief executive officer leading u process necessary fulfill responsibility corporation committed advocating public poli stakeholder engaging lobbying ef cies foster vigorous economic growth dynamic fort making political contribution company global economy welltrained productive complies law govern activity u workforce essential future competitiveness u federal law prohibits corporate political contri butions candidate running federal office council america member busi ness organization share common commitment participating political process free trade open market throughout ameri employee must comply company global ca industry sector represented council policy core value legal obligation clude manufacturing natural resource technology outlined lillys ethic source document red communication health care pharmaceutical book code business conduct section deal financial service ing government official political party detail appropriate employee conduct relates european federation pharmaceutical industry following topic association efpia comprises 29 national political financial support pharmaceutical industry association 43 lead payment official employee government ing pharmaceutical company involved public international organization research development manufacturing interaction government official initiated dicinal product europe human use efpias company employee vice versa mission promote pharmaceutical research development best condition company lilly membership number industry bring market medicine improve human business association well national inter health quality life around world national advocacy organization help u keep abreast best practice provide u valuable farmaindustria national association feedback enable u active citizenshipre pharmaceutical industry spain farmaindustria lated activity issue include follow nearly 250 member company group ing partial list number technical committee provide sup port member firm coordinate activity american chemistry council american chem government stakeholder istry council represents leading company engaged business chemistry council global environmental management initiative committed improved environmental health gemi nonprofit organization leading com safety performance responsible care panies mission providing forum common sense advocacy designed address major help business improve environmental health public policy issue health environmental safety performance increase shareholder value research product testing strengthen corporate citizenship association british pharmaceutical industry international federation pharmaceutical manu abpi trade association approximately 100 facturers association ifpma nonprofit company united kingdom produce pre nongovernmental organization representing major scription medicine member company research global researchbased pharmaceutical vaccine develop manufacture supply 90 company developed developing percent medicine prescribed uk country national health service japan pharmaceutical manufacturer association biotechnology industry organization bio jpma national association research trade association representing company specializ based pharmaceutical industry japan jpma work ing health care food agriculture industri 51 public policy promote greater public understanding find candidate dedicated improving rela solution pharmaceutical industry issue jpma tionship business government member international federation pharma candidate represent state district ceutical manufacturer association lilly operates facility large concen tration employee retiree pharmaceutical research manufacturer would lilly support impact america phrma represents country leading campaign researchbased pharmaceutical biotechnology company devoted developing medi lilly corporate political donation made based cines allow patient live longer healthier budget contribution budget deter productive life mined annually throughout year member company government affair organization bring pharmachemical ireland pharmachemical ireland forward specific recommendation company formerly known irish pharmaceutical contribution chief financial officer general chemical manufacturer federation committed counsel company must approve corporate furthering success growth pharmaceu contribution made united state gen tical industry ireland eral counsel international operation approves financial support given outside united state conference board board creates dis addition lilly belongs provides support seminates information management various trade association may sup marketplace help business strengthen port candidate political office contribute performance better serve society board political party official committee conduct research convenes conference forecast assesses trend publishes information analysis lilly pac brings executive together learn one lilly employee u may choose make another voluntary contribution eli lilly company political action committee pac entity funded verband forschender arzneimittelhersteller solely employee contribution lilly pac dona sociation researchbased pharmaceutical com tions made accordance budget panies trade organization researchbased determined annually lilly pac board lilly pharmaceutical company germany vfa work pac support divided equally federal promote therapeutic progress develop state level allocated among various candidate ment highquality pharmaceutical meet according specific recommendation society need company government affair organization em ployee pac member corporate political contribution elected official matter level im addition red book following process pact public policy issue affecting lilly place ensure compliance political con permitted law committed backing tribution law candidate party support public policy internal process related corporate pac contribute pharmaceutical innovation political financial support documented health need patient consider number pac governing board meet semiannually factor determining candidate sup employee outside government affair compose port example majority governing board computer software track pac corporate candidate historically voted announced political financial support ensure position issue importance lilly exceed contribution limit pharmaceutical innovation health care internal audit personnel conduct annual review candidate demonstrated leadership key corporate political support independent committee importance business public accountant conduct annual audit pac candidate demonstrate potential legis contribution lative leadership required disclosure corporate pac political financial support made federal election commission state election commis 52 public policy sion typically quarterly basis disclosure statement key issue required outside united state also made importation accordance local law lilly recognizes growing political public momentum legalizing importation company refund reimburse employ prescription drug canada country ee make personal contribution pac lilly opposes importation three key reason directly political party candidate 1 drug importation pose clear danger u prescription drug supply threatens abil 2005 lilly gave total 958057 political ity develop new medicine financial support united state 2 drug importation potential harm 312175 corporate contribution 645882 u economy loss job invest contributed lilly pac list ment research pharmaceutical industry 2005 corporate pac contribution available 3 importantly every federal agency responsible online httpwwwlillycomaboutcitizenshippac_ drug safety looked importation 061906pdf voiced safety concern american buy drug canadian website assume lobbying advocacy drug come canada however growing evi government action impact avail dence suggests drug shipped ability medicine patient lillys ability country canada united invest innovation maintain comprehensive state canadian health authority regulate government relation operation monitor influ medicine transshipped canada thus ence public policymaking process safety product cannot ensured state federal level united state effort ensure appropriate canadian dome tic supply address increasing level illegal 2005 lilly spent 4444391 federal lobbying importation pharmaceutical canada activity united state information patient safety issue caused importation lilly reported u congress accordance introduced program allocate supply lobbying disclosure act 1995 product canadian wholesaler based canadian patient demand following procedure place manage compliance federal state law relate intellectual property protection political lobbying lilly support strong effective protection intel lectual property right including patent protection summary state political contribution law pharmaceutical product pharmaceutical supplied public affair manager industry dependent upon protection public affair manager must file document grant inventor new product exclusive staterequired lobbying report timely manner yet limited period develop market prior submitting semiannual filing required product without protection pharmaceuti federal lobby disclosure act director cal research company would able recoup federal affair verifies accuracy reported lobby approximately 800 million invest ing activity average discover develop new drug lack lobbyist required comply applicable strong intellectual property right would gift ban requirement apply government chilling effect industry ability bring new representative lifesaving drug patient around world lobbying activity focused lilly recognizes importance international number key issue concern lilly effort seek improve harmonize intellec industry including importation pharmaceutical tual property protection throughout world intellectual property protection access cost continue support international trade agreement containment measure described facilitate implementation effective patent protection pharmaceutical product important market formerly provided inadequate protec tion lilly also recognizes significant contribu 53 public policy tions u trade law world trade competitive market force exist pharma organization wto rule made area ceutical industry best insurance exces intellectual property protection support sive drug price key driver continued discov continued use encourage developing country ery development innovative drug help provide effective patent protection pharma patient believe integrated privatesector ceutical product adherence wto standard coverage drug best way ensure access intellectual property protection stimulates economic patient miracle modern medicine growth increased investment retention local talent ensures availability innova counterfeiting tive medicine past year prescription pharmaceuti cal counterfeiting business evolved highly access cost containment measure sophisticated global endeavor encompassing special lilly produce medicine meet patient health ized distribution syndicate deliver authentic care need believe critical pa looking counterfeit tablet packaging label tients access product save regulated unregulated channel improve life access medicine function including product imported one country price health care coverage particularly another internet counterfeit drug united state reason lilly strongly manufactured illegally unsanitary condition support adding drug coverage u medicare might include little much active ingre program well finding way increase avail dients harmful ingredient counterfeit drug ability affordable health insurance pose public health risk lilly remains committed country additional factorssuch government patient safety company global anticoun terventions limit delay availability new terfeiting effort important component product price control health infrastructure concern public health ensures proper useplay major role deter mining whether new breakthrough medication lilly intent leader combating phar available maceutical counterfeiting initiated broad range action including addition enhanced lilly recognizes importance containing ri anticounterfeiting technology lilly product ing health care cost triggered aging population packaging change distribution sys increased public expectation health care tem lilly also partnering government non industry country need meet governmental organization trade association budgetary restriction andor reduce budget deficit strengthen enact enforce anticounterfeiting believe innovative pharmaceutical part law raise awareness lilly aggressively solution tonot cause ofthis problem pursuing litigating manufac governmental effort reduce drug access ture market counterfeit medicine step prescribing effective ultimately hurt exploitive action counterfeiter patient simply put shift cost com designed help protect patient place ponents health care system pharmaceutical trust company product properly integrated method treatment lead lower overall health care cost value pharmaceutical lilly advocate policy recognize value researchbased pharmaceutical industry pharmaceutical treating patient reducing uniquely qualified discover develop make total health care cost many instance pharma lifesaving innovative medicine available patient ceuticals eliminate need surgery hospi need measure artificially control talization slow reverse progress disease industry growth drug price counterproduc prevent disease developing allow people tive effort governmentmandated restriction return work sooner reduce return investment needed pharma ceutical firm engage costly research u example devoting approximately development new costeffective product 15 percent economy health care mea sured gross domestic product increasing pressure contain growth cost innovative costeffective pharmaceutical important 54 public policy way help contain overall health care cost sult society benefit health care solution become costeffective people live longer healthier active life lilly believe relying judgment health care decisionmakers provide pay health care way fully realize value pharmaceutical excessive inappropriate govern ment regulation including cost control stifle innovation necessary bring next generation lifesaving drug customer applying market principle health care system ensure delivery highquality lowercost health care encouraging innovation efficiency ulti mately benefit patient integrated approach health care keeping commitment provide cu tomers effective result lower cost lilly encourages transition current compo nentbased health care system comprehensive tegrated health care delivery system traditional approach trying control cost treatment element ignores fact limitation one ele ment may lead increased patient morbidity andor mortality resulting increase total health care cost example new drug may cost older one benefit new therapy may far outweigh increased expense eliminating expense hospitalization believe best approach treatment consider whole patient use whatever combination intervention therapy likely produce optimal clinical economic result element health care delivery process work alone 55 company information fiveyear data set economic indicator unit 2001 2002 2003 2004 2005 0405 net sale worldwide u million 11542 11077 12580 13858 14645 6 u sale u million 7364 6536 7176 7669 7798 2 western europe sale u million 1953 2155 2711 38584 41840 8 country sale u million 2225 2386 2696 23310 26632 14 cost revenue u million 2160 2177 2675 3224 347420 8 cash payment interest borrowing u million 126 55 45 0 32 cash payment common stock dividend u million 1207 1336 1443 1540 1655 7 retained earnings increase u million 1188 1089 970 254 3026 19 cash payment income tax u million 320 864 614 487 1780 266 product donation u million 177 204 222 338 453 34 cash contribution u million 38 27 29 46 58 26 total contribution u million 215 231 251 384 511 energy use unit 2001 2002 2003 2004 2005 0405 purchased electricity billion megajoules 506 499 527 6 purchased electricitysales mjm sale 040 036 036 0 natural gas billion megajoules 401 365 361 1 natural gassales mjm sale 032 026 025 6 coal billion megajoules 233 242 249 3 coalsales mjm sale 019 017 017 2 fuel oil billion megajoules 066 056 079 40 fuel oilsales mjm sale 005 004 005 33 lppropane billion megajoules 020 001 002 9 lppropanesales mjm sale 002 000 000 3 purchased steam billion megajoules 323 318 322 1 purchased steamsales mjm sale 026 023 022 4 purchased chilled water billion megajoules 047 057 062 8 purchased chilled watersales mjm sale 004 004 004 2 total energy consumed billion megajoules 1597 1539 1601 4 total energy consumedsales mjm sale 127 111 109 2 water unit 2001 2002 2003 2004 2005 0405 manufacturing billion liter 2840 3650 3524 3 normalized million litersm sale 226 263 241 9 water consumed billion liter 610 047 014 70 normalized million litersm sale 048 003 001 72 total water consumed billion liter 3890 3697 3538 4 normalized million litersm sale 266 267 242 9 hazardous material purchase unit 2001 2002 2003 2004 2005 0405 hazardous material purchase kgm sale 95100 80700 59300 27 air emission unit 2001 2002 2003 2004 2005 0405 co2 equivalent thousand kg 2271194 2215425 2277588 3 co2 equivalentssales thousand kgm sale 181 160 156 3 ozone depleting substance thousand kg 27 51 38 25 ozone depleting substancessales thousand kgm sale 00002 00004 00003 29 so2 equivalent thousand kg 4125 4271 3647 15 so2 equivalentssales thousand kgm sale 033 031 025 19 solvent emission unit 2001 2002 2003 2004 2005 0405 solvent emission percent use 043 046 040 13 voc emission unit 2001 2002 2003 2004 2005 0405 voc emission 976 913 6 waste unit 2001 2002 2003 2004 2005 0405 hazardous waste generated million kg 89559 108914 94163 14 hazardous waste generatedsales thousand kgm sale 712 786 643 18 56 fiveyear data set waste continued unit 2001 2002 2003 2004 2005 0405 nonhazardous waste generated million kg 46368 57667 61031 6 nonhazardous waste generatedsales thousand kgm sale 369 416 417 0 total waste recycled million kg 9844 10296 10189 1 total waste treated million kg 95239 117202 101166 14 total waste disposed million kg 21609 33805 34287 1 total beneficial reuse million kg 9235 5278 9552 81 total solid waste generated million kg 135927 166581 155194 7 total solid waste generatedsales thousand kgm sale 1081 1202 1060 12 beneficial reuse unit 2001 2002 2003 2004 2005 0405 material generated million kg 123 100 135 35 material generatedsales thousand kgm sale 98 72 92 28 contractor safety stats indiana site unit 2001 2002 2003 2004 2005 0405 recordable case rate per 100 employee 14 14 1 losttime case rate per 100 employee 01 02 120 lost workday per 100 employee 47 112 139 environmental spending unit 2001 2002 2003 2004 2005 0405 expense u million 8027 6115 24 expense percent revenue 058 042 28 capital u million 343 97 72 capital percent revenue 025 007 74 total u million 11457 7081 38 total percent revenue 083 048 42 environmental event unit 2001 2002 2003 2004 2005 0405 environmental event number 13 11 3 73 toxics release inventory unit 2001 2002 2003 2004 2005 0405 air million kg 025 022 014 37 air kgm u sale 354 1600 956 40 water million kg 015 019 016 14 water kgm u sale 215 1345 1093 19 land onsite disposal million kg 0035 001 001 5 land onsite disposal kgm u sale 492 069 068 0 land offsite disposal excluding potws million kg 015 004 006 63 land offsite disposal excluding potws kgm u sale 21 266 410 54 total million kg 123 09 059 045 037 19 total kgm u sale 829 3279 2526 23 serious injury illness unit 2001 2002 2003 2004 2005 0405 lilly usa per 100 employee 17 17 177 17 21 25 lilly global per 100 employee 16 16 16 16 17 4 serious ergonomic injury rate unit 2001 2002 2003 2004 2005 0405 lilly global per 100 employee 080 064 071 11 losttime case unit 2001 2002 2003 2004 2005 0405 lilly usa per 100 employee 039 043 035 042 042 0 lilly global per 100 employee 053 058 051 057 065 14 lost workday unit 2001 2002 2003 2004 2005 0405 lilly usa per 100 employee 39 57 58 69 803 16 lilly global per 100 employee 56 105 92 119 1007 15 fleet safety unit 2001 2002 2003 2004 2005 0405 lilly usa collision per million mile 107 91 749 779 721 7 pharmaceutical industry benchmark collision per million mile 92 873 834 806 761 6 note environmental data restated prior year due improvement data system use new waste category relevant pharmaceutical industry environmental data presented beginning 2003 base year many goal 57 company information award recognition business lilly netherlands ranked second 49 best fortune magazine 500 largest u corporation company work lilly climbed 152nd 2005 based revenue lilly finland ranked fourth best workplace america admired company 2005 2005 lilly ranked second among top 10 leading u lilly south africa recognized top 5 best pharmaceutical company fortune magazine company work south africa survey corporate reputation best pharmaceutical company south africa fortune global admired company lilly ranked third pharmaceutical category environment 2005 governor award environmental excellence science magazine best company scientist lilly arbor project funded supported lilly made list fourth consecutive year lilly foundation volunteer effort managed 2005 ranking second top 20 seventh iupui center earth environmental among biotech pharmaceutical company science award fall 2002 lilly honor 2005 mossy point nature pre serve parke county cooperative effort involving people worklife diversity lilly clinton fortune magazine 100 best company work lilly appeared list seventh consecu corporate citizenship tive year 2005 businessweek magazine philanthropic com working mother best company work panies 2003 lilly ranked first inkind 11th consecutive year lilly recognized donation fifth overall giving first among one best company working moth pharmaceutical company er 2005 lilly appeared top 10 seven lilly mexico recognized mundo ejecu time tivo executive world mexico prestigious lilly belgium among four company hon business magazine one country top 100 ored 2005 gender equality award company model corporate social responsibility 150 company lilly spain ranked third overall top pharmaceutical company great place work lilly spain also named among 100 best company work europe past three year lilly italy recognized within 30 best place work within top 10 best employer italy within 100 best workplace eu rope 2005 lilly mexico honored fourth consecu tive year one best company work mexico lilly brazil recognized within 150 best company work brazil best company woman work brazil 100 best company work latin america lilly germany recognized top 10 100 best employer europe lilly uk named employer choice second consecutive year earned motherwork best worklife balance award honored employer year award lilly poland nominated solid employer 2005 58 company information history lilly leading innovationdriven pharmaceutical 1918 john gw king go china serf corporation committed developing growing first sale representative abroad portfolio bestinclass pharmaceutical product help people live longer healthier 1919 dr gha clowes hired director active life long history meaningful scientific division medical innovation notably treatment 1923 iletin first commercial insulin product infection diabetes depression launched timeline illustrates significant event 1926 lilly laboratory clinical research history development responsible opened oversee clinical trial public corporation visit lilly web page wwwlillycom additional information 1928 lilly work harvard medical school corporate history significant medical produce first treatment pernicious breakthrough lilly anemia 1876 colonel eli lilly open new drug 1928 sale office opened shanghai china manufacturing company 1932 jk lilly sr retires eli lilly becomes president 1881 company incorporated first 1934 first nonus affiliate office established share stock issued london 1882 jk lilly sr named superintendent 1937 lilly endowment inc family trust fund research laboratory founded 1884 lilly sends first overseas shipment product 1939 lillys first manufacturing plant outside london united state opened basingstoke england 1886 scientific division established 1941 lilly supply blood plasma armed force company first chemist ernest eberhardt profit company hired 1943 company first penicillin product 1898 colonel lilly dy jk lilly sr take produced use armed force business 1944 mass production penicillin begin 1900 red lilly adopted company logo trademark 1948 jk lilly sr dy eli lilly becomes chairman board jk lilly jr named president 1905 sale reach 1 million 1953 jk lilly jr retires eugene n beesley named 1906 tradition philanthropy begin disaster president companythe first president relief san francisco earthquake outside lilly family 1907 eli lilly elder son jk sr join company 1954 tippecanoe laboratory manufacturing plant graduating philadelphia college open near lafayette indiana pharmacy 1954 agricultural research officially begin 1914 elis brother jk jr join company greenfield laboratory graduating pharmacy degree university michigan 1955 lilly manufacture first commercial shipment salk polio vaccine 1914 greenfield biological facility open produce vaccine antitoxin 1955 lilly stock becomes publicly traded 1916 jk lilly jr issue report employment 1957 darvon new painkiller introduced ensure fair equitable treatment employee 59 history 1960 elanco product company established 1994 company announces intent divest market agricultural animal health product medical device diagnostics business better focus core 1963 new herbicide treflan launched pharmaceutical business becomes company topselling product 1973 1982 1994 lilly announces definitive agreement sphinx pharmaceutical corporation 1964 keflin first cephalosporin antibiotic acquisition sphinx durham north introduced carolina u facility later renamed 1965 lilly open erl wood first research facility lilly research triangle park laboratory outside united state 2005 lilly close facility relocates operation indianapolis facility 1970 lilly stock listed first time new 1994 lilly acquires pc health system inc york stock exchange largest managedpharmaceuticalcare company 1974 sale reach 1 billion united state lilly sell company rite aid corporation 1998 1976 company celebrates 100year anniversary 1995 joint venture formed china invest 28 million build pharmaceutical 1977 eli lilly grandson founder dy manufacturing plant suzhou 1979 ceclor launched eventually becomes 1995 lilly launch internet site wwwlillycom world topselling oral antibiotic 1996 humalog insulin analog designed 1982 humulin lillys human insulin launched mimic body natural rapid insulin output world first pharmaceutical product response eating meal launched produced recombinant dna united state europe technology 1996 gemzar launched united state 1982 oraflex treatment arthritis withdrawn treatment locally advanced metastatic market death elderly patient pancreatic cancer reported 1996 zyprexa introduced united state 1986 prozac first revolutionary new class treatment schizophrenia eventually antidepressant drug launched belgium approved treat bipolar disorder u launch follows 1988 1997 pulmotil new treatment respiratory 1989 lilly dow chemical company form disease pig chicken approved dowelanco joint venture agricultural u food drug administration fda chemical lilly sell share company 1997 1997 company receives approval market evista first class new drug called 1989 elanco product company renamed elanco selective estrogen receptor modulators animal health prevention osteoporosis postmenopausal woman marketing begin early 1998 1990 church scientology attack safety efficacy prozac charge later proven 1998 lilly ceo randall tobias announces unfounded intention retire end 1998 tobias succeeded sidney taurel becomes ceo 1991 lorabid first new class oral antibiotic chairman board approved marketing 1999 actos new oral treatment type 2 diabetes 1993 lilly ceo vaughn bryson resigns amid developed takeda america research controversy issue surrounding development center inc approved company strategic direction bryson marketing united state succeeded former att president randall l tobias 60 history 2000 zyprexa reach prescribing milestone 2004 elector first new insecticide class prescribed 5 million consumer 20 year control fly louse 84 country worldwide since market entry cattle launched four year earlier surpassing prozac become lillys leading product 2004 cymbalta medication treat emotional physical symptom depression 2000 paylean new technology enhance leanness approved use u 2004 improve growth introduced pig 2005 cymbalta medication treat emotional 2001 lilly loses u market exclusivity prozac physical symptom depression approved use european commission 2001 company launch first separate e launched united kingdom business venture innocentive llc wholly owned enterprise use power 2005 strattera approved canada internet create enhance opensource country first nonstimulant treatment scientific research development attentiondeficit hyperactivity disorder later launched germany netherlands 2001 xigris breakthrough biotech therapy norway discovered developed lilly approved reduction mortality adult patient 2005 byetta exenatide approved sale severe sepsis high risk death launched u help patient type 2 diabetes improve blood sugar control 2002 lilly announces lillyanswers prescription reducing risk hypoglycemia drug program senior weight gain drug later approved argentina 2002 cialis medication treat male erectile dysfunction approved marketing 2005 lilly announces stop making four european union u launch follows different formulation insulin product 2004 including last two remaining animal sourced insulin approved human use 2002 strattera nonstimulant noncontrolled united state canada medication treat attention deficit hyperactivity disorder approved 2005 agreement principle announced 2002 forteo firstinclass medicine osteoporosis settle majority claim made u zyprexa product liability litigation patient stimulate new bone formation approved lilly usa begin promoting forteo december 2003 optaflexx approved u fda fed beef cattle increase red meat yield 2004 symbyax first fdaapproved medication treat bipolar depression launched united state 2004 alimta approved use cisplatin standard chemotherapy agent treatment malignant pleural mesothelioma 2004 lilly acquires applied molecular evolution inc ame headquartered san diego california u 2004 lilly launch publicly available online clinical trial registry wwwlillytrialscom 61 feedback report important tool communicating corporate citizenship performance progress feedback help u improve future please take online survey wwwlillycomabout citizenship send comment eli lilly company lilly corporate center indianapolis indiana 46268 attn social responsibility manager dc 1627 september 2006 eli lilly company right reserved 62